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DiazoxideIn recent years, it has become apparent that there exist several roles for respiratory complex II beyond me-
tabolism. These include: (i) succinate signaling, (ii) reactive oxygen species (ROS) generation, (iii) ischemic
preconditioning, (iv) various disease states and aging, and (v) a role in the function of the mitochondrial
ATP-sensitive K+ (mKATP) channel. This review will address the involvement of complex II in each of these
areas, with a focus on how complex II regulates or may be involved in the assembly of the mKATP. This article
is part of a Special Issue entitled: Respiratory complex II: Role in cellular physiology and disease.
© 2012 Published by Elsevier B.V.1. Introduction
Mitochondrial respiratory complex II/succinate dehydrogenase
(SDH)/succinate ubiquinone oxidoreductase (SQR); EC 1.3.5.1 (re-
ferred to in this review as complex II) is a 124 kDa protein complex
located on the matrix side of the mitochondrial inner membrane
[1]. It is comprised of four subunits: SDHA, SDHB, SDHC and SDHD.
SDHA, the ﬂavin-adenine dinucleotide (FAD) containing subunit and
SDHB, the iron–sulfur cluster containing subunit [2], are anchored
to the membrane by the cytochrome b containing membrane proteins
SDHC and SDHD. Complex II is a component of both the Krebs cycle
and the respiratory chain [3]. Complex II oxidizes the Krebs cycle
intermediate succinate, generating fumarate by passing electrons
from succinate to FAD. The electrons are passed along the 2Fe\2S,
4Fe\4S and 3Fe\4S centers in SDHB, ﬁnally reducing one molecule
of ubiquinone (co-enzyme Q10) to ubiquinol (reviewed in [4,5]). A
schematic is shown in Fig. 1.
Unlike respiratory Complex I or III, complex II does not pump
protons across the inner membrane. However, complex II is capabletory complex II: Role in cellular
1 Elmwood Avenue, Rochester,
P.S. Brookes).
sevier B.V.of reducing co-enzyme Q10, which can then be re-oxidized by com-
plex III and thus participate in the proton pumping Q cycle of oxida-
tive phosphorylation (Ox-Phos). It is generally believed that the
primary function of complex II is to maintain the reduced state of
the integral membrane Q pool [6]. Fully reduced co-enzyme Q10 has
been shown to function as an antioxidant, protecting mitochondrial
lipids and proteins from damage by constitutively produced reactive
oxygen species (ROS) [7].
There exist several roles for complex II beyond metabolism,
including succinate signaling, reactive oxygen species (ROS) genera-
tion, ischemic preconditioning, various disease states and aging, and
in the function of themitochondrial ATP-sensitive K+ (mKATP) channel.
This review will address the involvement of complex II in each of these
areas.2. Complex II inhibition and disease states
2.1. Cancer
Each of the four subunits of complex II is encoded by nuclear DNA.
This is a unique feature of complex II compared to the other respiratory
chain complexes, which contain additional mitochondrial DNA
(mtDNA) encoded subunits. Mutations in each of the four complex
II subunits in humans, although rare, have been identiﬁed (see
Table 1), and result in two general phenotypic classes. Loss of function
599A.P. Wojtovich et al. / Biochimica et Biophysica Acta 1827 (2013) 598–611or nonsense mutations typically produce slow growing or benign
(SDHC [8] and SDHD [9]) or highly aggressive (SDHB [10]) tumors of
the carotid body, classiﬁed as hereditary paragangliomas or pheochro-
mocytomas. In these cases there is typically no detectable SDH activity
in tumors [11]. Mutations in the succinate dehydrogenase assembly
factor 2 (SDHAF2) gene have also been identiﬁed, and produce tumors
similar to those caused by SDH-B/C/D mutations [12]. Tumorous
phenotypes only manifest after both copies of a particular SDH gene
have been lost and thus are classiﬁed as tumor suppressor genes [13].
The link between complex II and tumor formation may involve the
Warburg effect, wherein defects in Ox-Phos may play a role in driving
metabolism more toward glycolysis. The shift in metabolism, which
has been reported in SDH-derived pheochromocytomas, is thought to
be an important tumor survival mechanism [14].
The mechanisms through which loss of SDH activity promotes
tumor growth via the Warburg effect are debated, and are summa-
rized in Fig. 2. The most prominent theories pose that complex II
deﬁciency results in accumulation of metabolic intermediates that
signal activation of tumor-promoting pathways. The ﬁrst theory is
that loss of SDH activity leads to an increase in matrix succinate,
which freely enters the cytosol through the dicarboxylic acid
transporter. Succinate has been shown to act as a cytosolic signaling
molecule in the hypoxia-response pathway [15–17], by acting as an
inhibitor of prolyl hydroxylases (PHDs) [18]. In this signaling path-
way, cells respond to environmental oxygen levels though hypoxia
inducible factor (HIF)-1α. In the presence of molecular oxygen
HIF-1α is hydroxylated by PHDs and targeted by the E3 ubiquitinFig. 1. Complex II: Complex II is the succinate dehydrogenase enzyme of the TCA cycle oxidiz
transfers electrons from succinate through the FAD moiety of SDHA to three iron sulfur cent
heme iron, its role in electron transfer is uncertain. Complex II acts to increase the pool of re
Q10 then transfer electrons to complex III.ligase Von-Hippel–Lindau (VHL) protein for degradation [19]. In low
oxygen, or if PHD is inhibited, HIF-1α migrates to the nucleus
where it forms a heterodimeric transcription factor complex with
HIF-1β, activating genes that lead to increased glycolysis, angiogene-
sis, motility and survival [20]. This signaling pathway is generally
regarded as pro-tumor survival, enabling cancer cells to survive the
low oxygen environment of the tumor. In support of this mechanism
as a link between complex II mutations and cancer, increased cyto-
plasmic succinate levels have been conﬁrmed in SDH–A [21], –B
[22], –C and –D [11,23] mutants in association with an activated HIF
pathway (see also[24,25]). For further reviews see:[6,26–28].
Another key player in cancer, which has been linked to complex II
signaling, is the tumor suppressor p53. Mutant SDHB/D backgrounds
are associated with decreased levels of p53 and reduced p53 binding
to NADH ubiquinone oxidoreductase I [29], further strengthening the
link between decreased Ox-Phos and tumorous phenotype. Of
interest from a mitochondrial viewpoint, transcriptional targets of
p53 include the glycolysis-inhibiting gene, TP53-induced glycolysis
regulator (TIGAR), and the Ox-Phos activating gene, synthesis of cyto-
chrome c oxidase 2 (SCO2) [30,31]. Cellular p53 can be activated by
increased reactive oxygen species (ROS). When p53 is not bound to
the SCO2 gene, SCO2 is active and stimulates Ox-Phos, leading to
increased generation of reactive oxygen species (ROS) as a byproduct.
If ROS levels rise p53 is activated and translocates to the nucleus
where it binds to the SCO2 and TIGAR genes, inactivating and activat-
ing transcription, respectively. The activated TIGAR leads to increased
production of the ROS scavenger glutathione. Interestingly, bothing succinate to fumarate. The succinate ubiquinone oxidoreductase enzymatic activity
ers of SDHB and ﬁnally to Coenzyme Q10 via SDHC/D. Although the enzyme contained a
duced Coenzyme Q10 (QH2) in the mitochondrial inner membrane. Reduced Coenzyme
Table 1
Complex II mutant phenotypes associated with cancer and other diseases.
Subunit Gene locus Phenotype Malignancy MIM # Reference
SDHA 5p15.33 [55] Cardiomyopathy ? 613642 [209]
Leigh syndrome 256000 [55,210–212]
Mitochondrial Cx II deﬁciency 252011 [55,210–212]
Paraganglioma type 5 614165 [213]
SDHB 1p36.13 [214] Cowden-like syndrome High 612359 [215]
GIST 606764 [216]
Paragangliomas and GIST 606864 [217,218]
Paraganglioma type 4 115301 [10,219–223]
Pheochromocytoma 171300 [10,22,224]
SDHC 1q23.3 [217] GIST Low 606764 [216]
Paragangliomas and GIST 606864 [217]
Paraganglioma type 3 605373 [8,225]
SDHD 11q23.1 [226] Carciniod tumors intestinal Low 114900 [227]
Cowden-like syndrome 612359 [215]
Merkel a) – [227]
Paragangliomas and GIST 606864 [217]
Paraganglioma type 1 168000 [9,221,224,228–232]
Pheochromocytoma 171300 [229,233]
SDHAF1 19q13.12 [234] Mitochondrial Cx II deﬁciency 252011 [234]
SDHAF2 11q12.2 [12] Paraganglioma type 2 ? 601650 [12,235]
Legend. GIST, Gastrointestinal stromal turmors (GIST); Cx II, complex II.
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in the rare autosomal-dominant conditions Cowden syndrome (CS)
and Cowden-like syndrome (CSL). These syndromes are associated
with increased risk of tumors and hamartomas. In addition, CS
and CSL patients harboring SDHB and SDHD mutations have beenFig. 2. Metabolic and cancer related consequences of mutations in the SDH complex: 1) w
keeping cellular succinate levels low. Electrons are transferred to Coenzyme Q10 which can
SDH subunits inhibit or impair normal election ﬂow. Left: Increased succinate enters the
resulting in translocation of HIF-1α to the nucleus and increased transcription of genes for
ROS (either directly or via less scavenging by reduced Co-enzyme Q10). ROS can act directly
to ROS by increasing genes responsible for inhibiting glycolysis and ROS scavenging and
mutations in complex II can result in dysregulation of these genes.identiﬁed [29]. This suggests complex II may play a role in other
tumors in which both HIF and p53 are implicated.
Complex II has begun to be recognized as a source of ROS
[27,32,33]. Thus a second mechanism by which complex II mutations
may facilitate cancer is by the generation of damaging levels of ROS.ild-type SDH subunits form a functional complex II. Succinate is oxidized to fumarate
act as an antioxidant maintaining low levels of ROS. 2) Mutations in any of the four
cytosol where it inhibits prolyl hydroxylase (PHD) mediated degradation of HIF-1α,
tumor survival. Right: Disrupted electron ﬂow through complex II leads to increased
as a mutagenic agent on DNA or as a signaling molecule activating p53. p53 responds
decreasing genes involved in stimulating Ox-Phos. Loss of p53 in conjunction with
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subunit SHDA was capable of generating ROS [34]. Other complex II
subunits were later identiﬁed as a sources of ROS, speciﬁcally SDHB
[35–37], –C and –D [38] in yeast, SDHC in C. elegans [39] and mice
[40], and SDHB but not SDHA in human cells. In one study the in-
crease in ROS induced by SDHB mutants was found to be capable of
stimulating the hypoxia-response by inhibiting PHD [41]. However
in another study ROS generation by SHDB was not observed with
siRNA knockdown [42] or in human cancer cells exhibiting an SDHB
mutation [23]. The concept that complex II is a biologically signiﬁcant
source of ROS generation is relatively new, and the production of ROS
by various mutants of complex II subunits therefore requires further
analysis for a consensus to be reached.
2.2. Diabetes
ROS and succinate signaling, implicated in cancer formation as a
result of complex II mutations, have also been linked to diabetes. Di-
abetes is classically characterized by an inability to regulate blood
glucose levels due to the absence of (type 1) or acquired resistance
to (type 2) insulin. In diabetes, mitochondria are subjected to an in-
crease in substrate delivery as a result of prolonged increases in
blood glucose levels. This leads to an increased rate of succinate and
ROS generation [43–45]. In addition to its role as a signaling molecule
in the hypoxia response, succinate has been identiﬁed as a ligand for
the orphan G protein coupled receptor GPCR91 [46]. This receptor is
expressed in the kidney suggesting that increased succinate signaling
could contribute to renal hypertension, a disease that is closely linked
to diabetes.
A mechanism was recently proposed where succinate regulation/
accumulation is a key mediator of insulin release by pancreatic
β-cells [47]. Altered mitochondrial function as well as increased ROS
production were both implicated as pathogenic products of the dia-
betic state [48,49]. ROS generation was shown to be increased in insu-
lin deﬁcient rats respiring on complex I or complex II substrates. The
increased ROS was largely attributable to increased electron leak from
the co-enzyme Q10 binding site of complex III [50], or reverse electron
ﬂow through complex II [51].
Recent work has shown that the ﬂavoprotein subunit of complex II
(SDHA) is capable of generating physiologically relevant levels of ROS
in isolated mitochondria when concentrations of succinate were low
(400 μM) and the inner-membrane pool of co-enzyme Q10 was most-
ly in its reduced form (i.e. complexes I and III were inhibited). The au-
thors determined that complex II was capable of generating ROS
either from forward ﬂow of succinate to fumarate or from the reverse
reaction from reduced co-enzyme Q10. It has been demonstrated that
complex II was capable of reducing much smaller pools of co-enzyme
Q10 than any of the other respiratory complexes, and that complex II
was fully active upon reduction of the respiratory chain and in the
presence of ATP [6,52]. This suggested that the main function of
complex II is maintenance of the reduced co-enzyme Q10 pool. Fully
reduced co-enzyme Q10 serves as an antioxidant and helps protect
mitochondria from free radicals, whereas the semi-reduced form is
a pro-oxidant and is actually a generator of free radicals [53]. Overall,
these results suggest that both the succinate signaling and the ROS
generating mechanisms, potentially linking complex II dysfunction
and diabetes, are not mutually exclusive. For further review see:
[5,32,54].
2.3. Neurodegenerative diseases
Rare instances exist where loss of function mutations in SDHA
result in paragangliomas, however such mutations more commonly
result in a neurodegenerative disease known as Leigh's syndrome
[55]. Leigh's syndrome develops in early infancy and is characterized
by centers of necrotic cells in the brain stem and other regions of thecentral nervous system. SDH activity has been shown to be reduced
by 25–50% relative to normal tissue. Interestingly another common
neurodegenerative disease, Huntington's, has also been linked to dys-
functional SDHA [56]. Huntington's Disease (HD) is an autosomal
dominant neurodegenerative disease that affects the striatum and
cerebral cortex. People affected with HD typically show behavior
symptoms including loss of coordination, decline of cognitive facul-
ties, dystonia, and the involuntary movement disorder chorea [57].
Patients with HD have shown reduced mitochondrial complex II and
III activities [58,59], and decreases in the levels of SDHA and SDHB
have been observed in the striatum [60]. Tissue from postmortem
HD patents has increased oxidative damage indicative of increased
ROS (reviewed in [61]). Additionally systematic treatment of animal
models with complex II speciﬁc inhibitors 3-nitroproponic acid or
malonate cause phenotypes similar to HD, further supporting a link
between complex II and HD [62,63].
Finally, another neurological condition in which complex II may
play a role is Down syndrome (trisomy 21). It is now recognized
that at least some of the robust nature of Down syndrome individuals
(e.g., resistance to trauma) may originate from their having higher
levels of the cytoprotective gas hydrogen sulﬁde (H2S), since the
H2S generating enzyme cystathionine β synthase is encoded on chro-
mosome 21 [64]. Notably, SDH has been identiﬁed as a potential site
of inhibition by H2S [65], such that prolonged elevation of H2S may
lead to neurodegenerative effects [66] possibly mediated by complex
II inhibition.
2.4. Aging
A commonly held theory is that oxidative damage caused in part
by ROS from mitochondrial respiration contributes to aging, however
this model has been questioned recently, as roles for ROS as protec-
tive signaling molecules have been documented [67]. Furthermore,
recent evidence in the nematode C. elegans indicates that removal of
ROS detoxiﬁcation enzymes has little effect on worm lifespan
[68,69]. Similar results have recently been reported in mammals [70].
A mild decrease in mitochondrial respiration can extend lifespan
in many model organisms, including worms [71–73], and this effect
is conserved in mice [74,75]. In particular, mutations in complex I
and III subunits as well as in the clk-1 gene which encodes a protein
involved in ubiquinone synthesis confer longevity [76]. Interestingly,
while the ubiquinone product of the CLK-1 protein can transfer elec-
trons between complexes I and III or between complexes II and III, the
I–III transfer is speciﬁcally inhibited in the mutant [77]. Not coinci-
dentally, complexes I and III are classically thought to be the main
sites of ROS production in the respiratory chain, and ROS production
is critical for lifespan extension in the mutants [78].
Furthermore, lifespan is sensitive to oxygen concentration and
may be HIF dependent [79,80], though other signaling pathways ap-
pear to respond to mitochondrial dysfunction as well [78,81–84].
The interface between these pathways may ultimately determine
the rate of aging. In concert these results argue that ROS produced
by complexes I and III as a result of decreased respiration can act as
a signal that promotes longevity.
In dramatic contrast to the life-extending effects of mutations in
complex I and III subunits, the mev-1 mutation in the SDHC subunit
of C. elegans complex II also results in increased ROS production, but
decreases lifespan [85]. This association between complex II dysfunc-
tion and reduced lifespan was strengthened by the ﬁnding that inde-
pendent mutation of sdhb-1 (SDHB) resulted in a phenotype that was
indistinguishable from mev-1, including increased ROS production
[86]. Many aspects of the mev-1 mutant phenotype are recapitulated
in Drosophila [87], and introducing the mev-1 mutant into mouse
SDHC results in excessive apoptosis, low birth weight and neonatal
growth retardation due to ROS overproduction and mitochondrial
stress [88]. Although more apoptosis occurs in the mev-1 model
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accumulation of aging biomarkers, suggesting that it is not merely
inappropriately timed death occurring, but rather accelerated aging.
There are also unique metabolic signatures that differentiate
complex II mutants from those in complexes I and III, and it has
been suggested that long-lived mit mutants utilize a novel metabo-
lism normally seen under hypoxic conditions [89]. However, muta-
tions in ucp-4 that decrease succinate-driven complex II respiration
suppress shortened lifespan in mev-1 mutants [90], suggesting that
it is the physical act of respiring through the mutant complex II that
is damaging. Taken together, these results support the idea that ROS
production from complex II differs in either quantity or quality from
that generated by complexes I and III. For example, one possibility is
that the amount of superoxide produced by complex II is much great-
er than I or III, and merely overwhelms the detoxiﬁcation processes.
Another possibility is that the ROS from complex II is distributed in
a way that it is less easily detoxiﬁed or more easily creates molecular
damage. A third possibility is that the ROS arising from complex
II function (or dysfunction) may not be able to elicit adaptive re-
sponses through similar signaling pathways as ROS from complexes
I and III.
Regardless, there appears to be an evolutionary bias toward
protecting complex II function. For example, Drosophila that have
been adapted to live under otherwise lethal hypoxia exhibit nearly
a two-fold decrease in complex II activity, with only mild changes
to the other respiratory complexes and consequently less superoxide
leakage occurring during mitochondrial respiration [91]. With respect
to mitochondrial disease, for nearly all the other complexes (esp.
complexes I and IV), there exist age-dependent correlations for muta-
tions in the complex and in particular the mtDNA encoded subunits,
which are acutely subject to mitochondrial ROS. However, complex
II is entirely nuclear-encoded, which may be a kind of a safe-haven,
removed from the ROS onslaught that the other mtDNA encoded
complexes are bombarded with, and protected by nuclear DNA dam-
age repair enzymes. It is intriguing to speculate that this is because
the effects of complex II dysfunction are so detrimental.
A recent study on mitochondrial biochemistry in the developing
mouse heart reported on a preference for complex II over complex I
as the electron entry point in the respiratory chain at embryonic
day 9.5, which switches to a preference for complex I by embryonic
day 13.5 [92]. A second interesting ﬁnding of this paper is that cellular
ROS levels rose at the time complex II was the preferred electron
entry point [92]. This work provides evidence that complex II is
important in early development as well as aging.3. Ischemia reperfusion (IR) injury and ischemic
preconditioning (IPC)
Complex II and ROS are implicated in the acute pathology of ische-
mia reperfusion (IR) injury and the following sections are focused on
the cardiac model. Key hallmarks of IR injury are a loss of oxygen and
substrate supply, acidiﬁcation, mitochondrial Ca2+ overload, loss of
adenine nucleotides, permeability pore transition opening, and the
overproduction of ROS [93]. One mechanism of protecting the heart
from stress is ischemic preconditioning (IPC), whereby brief periods
of ischemia prior to a longer ischemic insult provide protection
against IR injury [94]. Mitochondria have emerged as a critical
component of the signaling mechanisms involved in IPC [95–97].
The precise mechanism of IPC is elusive but involves an array of sig-
naling cascades activated by a mild increase in ROS [98–100]. Many
of these signaling events converge on the mitochondrion and the
protection of IPC can be mimicked via the administration of pharma-
cological agents that act on the mitochondrion; in particular, complex
II and the mitochondrial ATP-sensitive K+ channel (mKATP) are
targets of protective compounds [96].3.1. Complex II and IPC
IPC is known to inhibit mitochondrial electron transport and not
surprisingly mimicking this reduction in activity with mitochondrial
respiratory inhibitors is cardioprotective [97]. IPC reversibly inhibits
complex II [101,102]; however, the mechanism remains unclear.
One potential mechanism involves formation of endogenous complex
II inhibitors. ROS are an important component in IPC signaling, and
under conditions of oxidative stress the complex II inhibitor malonate
can be generated [102] via the non-enzymatic decarboxylation
reaction between H2O2 and oxaloacetate (OAA) [103]. The competi-
tive inhibitor malonate is also cardioprotective [102,104].
While both malonate and OAA are inhibitors of complex II,
malonate-mediated inhibition is more readily reversed. Thus, a
malonate-occupied complex II would be desirable at reperfusion
[97]. However, the removal of malonate from complex II requires
ATP [105], which is not immediately available in early reperfusion.
This suggests that malonate removal and reversal of complex II
inhibition following ischemia may be a gradual process. As such,
malonate may be considered an appropriate inhibitor, since it is
easy to remove at the right time. Furthermore, malonate formation
from OAAmay offer additional beneﬁt since a decrease in the concen-
tration of OAAwould prevent rapid re-introduction of acetyl-CoA into
the Krebs cycle at reperfusion. Effectively, malonate formation sup-
ports a “gradual wake-up” of the respiratory chain from ischemia/
reperfusion, thereby providing cardioprotection [97].
In addition to an ROS-mediated mechanism of complex II inhibition
during IPC, reactive nitrogen species (RNS) may also participate. For
example, nitro-linoleate is generated during IPC, is cardioprotective
[106,107] and inhibits complex II [108]. Also, nitroxyl (HNO) inhibits
complex II [108,109] and is cardioprotective [108,110]. These
compounds react with important thiols in complex II and suggest
that complex II may act as a redox sensor. Notably, complex II can
also be glutathionylated on the SDHA subunit, resulting in an increase
in activity [111]. In IR injury, SDHA becomes deglutathionylated,
resulting in impaired activity [111]. It is currently unknown if protec-
tive interventions such as IPC are capable of modulating the degree of
complex II de-gluathionylation that occurs in subsequent IR injury. If
so, this would provide another mechanism of control over complex II
during the critical early reperfusion phase.
Finally, while themodulation of complex II by endogenous inhibitors
may provide protection, it has recently become apparent that more po-
tent and speciﬁc complex II inhibitors such as 3-nitropropionic acid
[112,113] and atpenin A5, [104,114] are cardioprotective, opening the
door for complex II as a therapeutic target in IR injury.
3.2. complex II and the mitochondrial ATP-sensitive K+ channel (mKATP)
The mechanism of complex II inhibition and how it is protective
remains unclear, but is thought to involve the mitochondrial
ATP-sensitive potassium channel (mKATP). The mKATP is a central
component of IPC-mediated protection, such that channel openers
can mimic IPC [115,116] and channel blockers block IPC [117–119].
The mitochondrial K+ cycle plays an established role in regulating
mitochondrial volume and function [120,121]. The precise mecha-
nism of protection elicited by the mKATP remains elusive but may in-
volve the regulation of mitochondrial matrix volume and adenine
nucleotide status, as well as the prevention of mitochondrial Ca2+
overload and the overproduction of ROS [122,123].
Despite the central role of the mKATP in protecting the heart, the
molecular composition of the channel remains debated (see Fig. 3).
Similarities in pharmacologic agents and channel characteristics sug-
gest that the mKATP may be related to the well-deﬁned surface KATP
channel. However, mKATP speciﬁc agents (e.g., diazoxide and 5-HD)
which are used to distinguish the channel from the surface KATP
[115] suggest a variation in structure. Furthermore, the mKATP speciﬁc
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hibitors open mKATP [102,104,104,108,113]. While the relationship
between complex II inhibitors and the mKATP has been alluded to,
this relationship remains to be fully characterized.
The combination of a lack of a consensus structure and ‘off-target’
effects of channel modulators has led to the hypothesis that the
mKATP may be composed of known mitochondrial components such
as complex II, rather than canonical KATP subunits. The evidence for
each hypothesis is provided in the following sections, with current
models for mKATP shown in Fig. 3.
3.3. Molecular composition of the mKATP
3.3.1. Canonical Kir6.x/SUR composition?
A canonical surface KATP channel is made of a pore-forming in-
wardly rectifying K+ channel subunit (Kir6.1 or Kir6.2) coupled
with an auxiliary sulfonylurea receptor (SUR1, SUR2A or SUR2B)
subunit [124], in an octomeric conformation (Fig. 3). Agents which in-
hibit (e.g., glyburide) or activate (e.g., pinacidil and nicorandil) the
surface KATP also affect the mKATP, and following the discovery of
ATP-sensitive K+ currents in mitochondria [125] efforts were focused
on ascribing a Kir6.x/SURx composition to the channel. However,
Kir6.x/SURx are not found in mitochondrial proteome databases
[126] and they lack canonical mitochondrial targeting sequences
[127]. It has therefore been proposed that other mechanisms that
involve structural features such as protein folding [128] or post-
translational modiﬁcation [129] may target these proteins to the
mitochondrion.
Previous approaches to identify the mKATP have relied heavily on
immunologic techniques and yield a complicated outlook, with re-
ports of Kir6.1 [130–132], Kir6.2 [133], both [134–136] or neither
[137] in mitochondria. Moreover two widely used anti-Kir6.1
antibodies have been shown to recognize mitochondrial proteins
not related to a Kir subunit [138]. Trafﬁcking of a Kir6.x subunit to
the cell surface requires its association with a SURx and suggests
that if a Kir6.x subunit exists in the mitochondrion, it would be
associated with SURx. Recently, a splice variant of SUR2 was found
to localize to mitochondria, however it did not contribute to mKATP
activity [139].
The mKATP is central to IPC-mediated protection, and while knock-
out mice for Kir6.1, Kir6.2, SUR1 and SUR2 [140–142] exist,
confounding vascular effects preclude deﬁnitive evidence for the
role of Kir6.x/SURx in IPC [140,143–145]. A key example is that
many of these KATP channel mice exhibit diabetes, which is knownFig. 3. Current models for the mKATP: 1). The mKATP may be composed of a Kir/SUR octamer.
immunoreactivity of mitochondrial inner membrane fractions to anti-Kir and anti-SUR anti
proteins adenine nucleotide transporter, phosphate carrier, mitochondrial ATP binding casse
activity in reconstituted proteo-liposomes containing these ﬁve proteins [137]. 3) The mKAT
potassium channel, ROMK) [148].to diminish the response to IPC [144]. Previous measurements of
mKATP activity relied on ﬂavoprotein ﬂuorescence as an indicator of
channel activity and found that the loss of Kir6.1 or Kir6.2 in mice
does not affect ﬂavoprotein ﬂuorescence [146,147].
More recent studies suggest an alternative mKATP composition,
hypothesizing that a variant of Kir1.1 (the canonical renal outer med-
ullary K+ channel, ROMK) may be the pore-forming subunit of the
mKATP [148]. However, reconciliation of several inconsistencies
would help to validate this claim. For example, the ATP sensitivity
of ROMK is much higher (K1/2=2.3 mM) [149] than that measured
for the mKATP (1–25 μM) [150,151]. Furthermore, the tricyclic antide-
pressant drug ﬂuoxetine (Prozac) is known to inhibit both the mKATP
(IC50 2.4 μM) and IPC [151], but Kir1.1 is insensitive to ﬂuoxetine
[152,153]. Direct measurements of mKATP activity from genetic
models (e.g., ROMK knockout mice), which are currently lacking,
may be necessary to designate mKATP channel status to Kir1.1. There-
fore, while Kir1.1 may indeed be present in mitochondria, its role in
IPC remains to be fully elucidated.
The mKATP channel activity is conserved across a range of species
and cross-species comparisons may help to identify or rule out cer-
tain candidate genes. For example, while the mammalian genome
codes for 15 Kir isoforms, the C. elegans Kir family contains only
three genes, irk-1, irk-2, and irk-3. Using the power of worm genetics,
we recently showed that a triple knockout irk-1/2/3 worm exhibited
perfectly normal mKATP activity and preconditioning [154]. These
data demonstrate that at least in C. elegans, the mKATP is not derived
from the Kir family. While more work is needed to fully elucidate
the role of canonical Kir/SUR subunits in the mammalian mitochon-
drion, these results suggest that non-Kir proteins should also be
considered as candidates for the mKATP. In this regard, the lack of con-
sensus regarding off-target effects of KATP agents (described below)
has led to the hypothesis that the mKATP is composed of known mito-
chondrial proteins, including complex II.
3.3.2. Alternative hypothesis: a complex II composition for mKATP?
The notion that the mKATP resembles the surface KATP was largely
built on the use of small molecules. Inhibitors and activators of the
deﬁned surface KATP had expected effects on isolated mitochondria
K+ ﬂuxes. However, most of these molecules have off-target effects
on mitochondrial function (reviewed in [155]). For example,
glyburide is a sulfonylurea used to treat type 2 diabetes. Via its inter-
action with the SUR (140–180 kDa), glyburide inhibits KATP channels
[156]. Glyburide also prevents the protective effects of mKATP activa-
tion. Studies using labeled glyburide found that it binds to a 28 kDaEvidence is based on the composition of known KATP channels from cell membranes and
bodies. 2) The mKATP may be composed of a super complex of known inner membrane
tte protein 1, complex II and complex V. This hypothesis is based on detection of mKATP
P is proposed to be composed of a tetramer of the Kir1.1 protein (renal outer medullary
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These weights are signiﬁcantly smaller than the apparent molecular
weight of the surface KATP channel, and they may represent a mito-
chondrial targeted splice variant [139] or a SUR-independent target.
In this regard, glyburide at high doses inhibits respiration [159,160]
and molecular modeling demonstrates that it may interact with the
adenine nucleotide translocator (ANT) [161]. Work in our laboratory
(unpublished) has found that a BODIPY conjugate of glyburide binds
to intact complexes I and V on clear-native electrophoresis gels.
Perhaps the most widely used tool related to mKATP studies is
diazoxide. While diazoxide is a general KATP opener, it is more potent
at opening the mKATP and is considered a mKATP speciﬁc agonist
[115]. However, diazoxide has off-target mitochondrial effects, such
as mitochondrial uncoupling at high concentrations, and inhibition
of complex II. It is important to note that while diazoxide does impli-
cate a relationship between complex II and the mKATP, other channel
openers such as cromakalim do not affect complex II activity. This
suggests that complex II is not the sole component of the channel
and may represent an important regulator. Nonetheless, these effects
of diazoxide on complex II are interesting when viewed alongside
another characteristic of complex II—namely the fact that ATP alloste-
rically activates complex II activity [102,162]. This suggests an inverse
relationship between complex II and mKATP activities.
Rather than serving as the mKATP channel alone, it has been pro-
posed that complex II may form a complex with other known mito-
chondrial proteins, to elicit mKATP channel activity [137]. This
complex includes the phosphate carrier, mitochondrial ATP-binding
cassette protein-1, the ANT, and respiratory complex V [137]. These
proteins were puriﬁed as a fraction from mitochondria, and while
the fraction contained over twenty proteins identiﬁable by silver
staining, these 5 proteins were the majority components [137]. The
puriﬁcation and reconstitution of these proteins into proteoliposomes
reproduced the pharmacologic characteristics of the mKATP channel
[137], including the ability of complex II inhibitors to stimulate K+
ﬂux. Thus, it was suggested that these proteins may exist in a
super-complex comprising the mKATP channel. There is a precedence
for super-complexes in the respiratory chain [163] and evidence for
coupling between complex II and complex V deﬁciencies in humans
[164]. It has also been suggested that diazoxide interacts with com-
plex V, facilitating the binding of its endogenous inhibitor to the
F(1) subunit [165] and reversibly inhibiting ATP hydrolysis.
A shortcoming of this proposed mKATP super-complex is the lack
of an actual K+ transporting protein in its composition [137]. All
known K+ channels contain the consensus sequence GYG in their
pore region, providing a selectivity ﬁlter for potassium. There is
some evidence that the ANT can transport K+ [166,167], and molecu-
lar modeling suggests that the KATP blockers glyburide and 5-HD can
interact with the ANT [168], but ANT does not have a GYG motif. Thus
the possibility remains that a low abundance [169] bona ﬁde K+
channel subunit may be present in the super-complex, to confer
mKATP activity.
The functional and pharmacologic evidence supporting the hypoth-
esis that complex II is a component or regulator of themKATP channel is
summarized as follows: 1) complex II inhibition is observed in IPC
[101,102], 2) mKATP inhibitors stimulate complex II [102,162,170],
3) mKATP openers inhibit complex II [102,104,170,171], 4) complex II
inhibitors open mKATP and are cardioprotective in a manner sensitive
to mKATP blockade [104,108,113]. The array of structurally distinct
complex II inhibitors capable of protecting by opening mKATP range
from endogenously generated (e.g., malonate) to potent and speciﬁc
(e.g., atpenin A5). These inhibitors interact with complex II at different
sites and all elicit mKATP activity.
One unique aspect that has arisen from these studies is that, like
diazoxide, the amount of inhibitor required for maximal mKATP activ-
ity is much lower than that required for the enzymatic inhibition of
complex II. For example, atpenin A5 has an IC50 for complex II activityof 10 nM, while 1 nM yields maximal mKATP activity. Taking advan-
tage of the potency of atpenin A5, the relationship between complex
II and mKATP activity was quantiﬁed, with the ﬁnding that only 0.4% of
complex II molecules were necessary to elicit maximal mKATP activity
[169]. Not only does this account for the low abundance of the
channel [172] it also demonstrates that bulk complex II activity is
not affected by the presence of the inhibitor. These results imply
that the speciﬁcity of diazoxide for the mKATP vs. the surface KATP
may reside at the level of complex II [169]. Finally, it is notable that
all known complex II inhibitors can activate the mKATP channel even
when mitochondria are respiring on complex I linked substrates
(e.g. pyruvate plus malate). This suggests that complex II does not
need to be enzymatically active to participate in the mKATP.
4. What is the endogenous physiologic role of the complex
II–mKATP channel interaction?
As discussed in the preceding sections, a role for both complex II and
mKATP channels in IPC has been well established. However, these pro-
teins clearly did not evolve for this purpose. Therefore, how do they in-
teract under normal conditions, and what is their baseline/endogenous
physiologic role in the absence of a stress signal such as IPC?
4.1. A ROS signal?
A key question in the mKATP ﬁeld is how complex II transmits a
signal to induce mitochondrial K+ uptake, and the physiologic
relevance of this phenomenon. One proposed mechanism is that, in-
dependent from direct complex II ROS generation [173], complex II
inhibition may trigger ROS formation by a different part of the respi-
ratory chain (complex III), and this is responsible for subsequent pro-
tective signaling [174]. In brief, the reduction state of the co-enzyme
Q10 pool can inﬂuence complex III ROS production, especially when
complex III is inhibited with antimycin [32]. When electrons are
supplied via complex II, inhibitors of complex II can stimulate
antimycin-induced ROS production in a bell-shaped response, as a
consequence of the redox state of the co-enzyme Q10 pool [175,176]
(recently reviewed in [177]). Since mild ROS generation is a critical
component of IPC, this mechanism was hypothesized to mediate the
protective effect of complex II inhibitors and diazoxide, completely
independent of any role for the mKATP channel [174]. However, sever-
al pieces of evidence suggest this ROS phenomenon is independent of
complex II's role in the mKATP or in IPC. These will now be discussed
in detail:
(i) The increase in ROS is dependent on succinate: The increase in
ROS with complex II inhibitors was only observed when mito-
chondria respired on succinate and not present when complex
I or complex III were used as electron sources [174,178]. On the
contrary, complex II inhibitors can open the mKATP even when
mitochondria respire on complex I or complex IV linked sub-
strates [102,104,104,169], or when channel components are
reconstituted in proteoliposomes or lipid bilayers [137]
(reviewed in [179]).
(ii) ROS generation requires the presence of antimycin A: In the ab-
sence of antimycin, complex II inhibitors did not increase ROS
formation, rather the addition of inhibitors resulted in a de-
crease in ROS [174,176]. Another study demonstrated a decrease
in ROS formation with complex II inhibitors in the presence of
succinate, rotenone andmyxothiazol [173]. Furthermore, modu-
lation of the co-enzyme Q10 pool redox state by cyanide [176] or
loss of cytochrome c does not increase complex III ROS [180].
Thus, the increase in ROS induced by complex II inhibitors ap-
pears unique to antimycin. Contrastingly, studies demonstrating
mitochondrial K+ ﬂux induced by complex II inhibitors did not
have antimycin present [102,104,108,137,151,169,181].
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hallmark of mKATP activity is its sensitivity to K+. In this regard,
both mitochondrial K+ ﬂuxes and the protective effects of com-
plex II inhibition are K+ sensitive [102,104,108,113,137,151],
while antimycin induced ROS generation was insensitive to
loss of K+ [174,178]. Similarly, both mitochondrial K+ ﬂuxes
and the protective effects of complex II inhibition are sensitive
to mKATP channel inhibitors [102,104,108,113,137,151,182],
while antimycin-induced ROS generation is not [174,178].
These ﬁndings highlight that ROS generation in response to
complex II modulation is completely independent from mKATP
and mitochondrial K+ ﬂux.
(iv) ROS generation via thismechanism requires higher concentrations
of complex II inhibitors than required to activate the mKATP chan-
nel [174]: Diazoxide at high concentrations (>100 μM)may result
in uncoupling or activate surface KATP channels. When used at ap-
propriate concentrations (10–30 μM) diazoxide displays mKATP
speciﬁcity [115]. Recently we demonstrated that a low concentra-
tion of the complex II inhibitor atpenin A5 activatesmKATP activity
in isolated mitochondria and results in mKATP-sensitive cardio-
protection [104]. Moreover, this concentration (1 nM) is without
effect on bulk complex II enzymatic activity [169]. However, the
antimycin-induced ROS generation was only seen at atpenin A5
concentrations (5–50 nM) that would inﬂuence complex II activi-
ty and subsequently the state of the co-enzyme Q10 pool.
Together, these ﬁndings suggest that the mKATP activity and
cardioprotection mediated by complex II inhibition are independent
of antimycin-induced ROS generation. The currently availableFig. 4. Complex II/mKATP interaction in energy sensing: “Classical” respiratory coupling is s
phosphorylating (state 3) conditions depending on availability of ADP. Additional levels of co
leads to preferred electron entry via complex I, which in turn increases the efﬁciency/stoich
true when ATP is high (left side). (ii) Low ATP disinhibits (opens) the mKATP channel, leadi
contact between the inner and outer membranes (IM/OM), enhancing the creatine kinase sh
the mKATP channel, the matrix shrinks, and IM/OM contact decreases, lowering ATP transpoevidence does not favor ROS generation as an intermediate signal
between complex II, mKATP, and cardioprotection/IPC.
4.2. Energy sensing
ThemKATP has been described in humans, rats, mice, plants, amoeba,
T. cruzi and C. elegans [125,133,183–186]. Although the primary research
interest in the mKATP ﬁeld is cardioprotection, most of these species do
not have a heart or suffer from any cardiac disease, suggesting that the
channel may have an evolutionarily conserved physiologic role. If the
mKATP is a super-complex of complex II, the phosphate carrier, mito-
chondrial ATP-binding cassette protein-1, ANT, and complex V, this
may suggest a relationship betweenmitochondrial K+ ﬂuxes and bioen-
ergetics. This view is compatible with the energy-sensing capabilities of
the canonical surface KATP channel. While other metabolic sensing path-
ways such as mTOR [187], SIRT3 [188] and AMPK [189] may involve
changes in complex II [190–192], they integratemore long term changes
in metabolic state. In contrast, the complex II/mKATP system may re-
spond more rapidly to energetic status. Since regulation of metabolism
is known to be a strategy for protecting the heart against ischemia
[97,193], any component which can regulate metabolism or the ener-
getic status of the mitochondrion (e.g. mKATP) may also be a critical
component of a cell's cardioprotective machinery.
The complex II/mKATP complex is hypothesized herein to exert
control over metabolism in addition to “classical” respiratory control
(i.e., state 3/state 4), to meet the cell's energy demand. These mecha-
nisms are shown in Fig. 4. First, the introduction of electrons into the
respiratory chain is competitive, such that the oxidation of succinate
at complex II inhibits the oxidation of NADH at complex I [52]. Sincehown in the center, in which mitochondria transition between quiescent (state 4) and
ntrol are shown in outer circuits, including: (i) ATP is a complex II activator, so low ATP
iometry of Ox-Phos (H+/e− ratio), increasing ATP synthesis (right side). The reverse is
ng to K+ and water entry and swelling of the matrix (right side). This leads to greater
uttle and ATP availability for the cell. When ATP is low, the cycle reverses, as ATP closes
rt to the cytosol (left side).
Table 2
Complex II modulators.
Reagent Conc. Effects mKATP effect
ATP mM Activate [102,162] Inhibit [102,182,198]
Atpenin A5 nM Inhibit [104,114,173,174] Activate [104]
Diazoxide μM Inhibit [171] Activate [102,115,182,198]
HNO μM Inhibit [108,109] Activate [108]
LNO2 μM Inhibit [108] Activate [108]
Malonate mM Inhibit [137] Activate [102,104,137,181]
3-nitropropionate mM Inhibit [236,237] Activate [113,137]
Oxaloacetate μM Inhibit [52,102,238,239]
Harzianopyridone nM Inhibit [114]
carboxin μM Inhibit [114]
HQNO μM Inhibit [114]
TTFA μM Inhibit [114]
Legend. HQNO, 2-heptyl-4-hydroxyquinoline N-oxide; TTFA, 4,4,4-triﬂuoro-1-(2-
thienyl)-1,3-butanedione.
606 A.P. Wojtovich et al. / Biochimica et Biophysica Acta 1827 (2013) 598–611complex II does not pump protons, the H+/e− stoichiometry is lower
when electrons enter at complex II. Thus, the ratio of electron entry
between complex II vs. I can lead to changes in the overall efﬁciency
of Ox-Phos. This becomes an important mechanism of regulating
metabolism, when coupled with the fact that complex II is activated
by ATP. Under conditions of high ATP, complex II is active, thus
inhibiting complex I, and lowering H+/e−, leading to inefﬁcient
Ox-Phos. Alternatively, when ATP is low, complex II activity is also
low, so more electrons enter at complex I, and H+/e− rises to meet
the demand for more ATP [52].
In a second novel mechanism of control, regulation of mitochondri-
al matrix volume by the mKATP channel may serve as a coupling link
between ATP levels and the activity of the Ox-Phos machinery. Mito-
chondrial K+ uptake is followed by osmotically obligedwater, resulting
in matrix swelling [120]. Matrix volume controls efﬁcient energy trans-
fer (via the creatine kinase (CK) shuttle system), and controls the activ-
ity of matrix enzymes necessary for ATP production, and is critical to
the regulation of energy metabolism [121,172,194–200]. As such,
when ATP levels are high, the mKATP is inhibited, the matrix shrinks,
and the resulting loss of inner/outer membrane contacts decreases
the efﬁciency of the CK shuttle system. In contrast, low ATP levels facil-
itate K+ inﬂux via mKATP, leading to matrix swelling, which enhances
inner/outer membrane contact and stimulates efﬁcient shuttling of
high energy phosphates.
As depicted in Fig. 4, the combination of the inﬂuence of K+ on
mitochondrial volume and metabolism, with complex II activity and
energy sensing capabilities, suggest that these phenomena may be
components of a concerted mechanism to modulate Ox-Phos to
meet energy demands. This proposed physiologic role of the mKATP
also makes the channel an important component of how the cell
responds to pathologic conditions (e.g., IR injury).
4.3. Mitochondrial ﬁssion/Fusion?
Recently however, an intriguing link has been proposed between a
super-complex type mKATP channel (see Section 3.3.2) and Charcot–
Marie–Tooth disease type 2A [181]. Typically, this disease is associated
withmutations in mitofusin 2 (MFN2), which is an important regulator
of both mitochondrial fusion [201] and membrane potential [202]. No-
tably, the study found that a mouse model carrying an MFN2 mutation
had a defect in both complex II (40% reduction) and complex V (30%
reduction) [181]. Interestingly, the lost enzymatic activities were re-
versed by the mKATP inhibitor 5-HD. Furthermore, the phenotype
could be mimicked by the mKATP channel opener diazoxide [181].
What remains unclear, is how a mutation in MFN2 (an outer mem-
brane protein with the bulk of its structure facing the cytosol) commu-
nicates with complexes II and V in the inner membrane. However, this
study highlighted a role for complex II (and complex V) and the mKATP
in disease. Further studies are needed to investigate the link between
mitochondrial K+ ﬂux and ﬁssion/fusion.
5. Conclusions and future directions
Complex II inhibition plays a dual role in biology, being both a de-
structive force in many disease states and also a protective mediator
in others. Complex II “the destroyer” is capable of generating ROS in
a manner that may be different in quantity or quality from complexes
I and III. The genes encoding complex II are protected in the nucleus
and may represent a mechanism to protect the cell from devastating
ROS production resulting from mutated complex II. Complex II “the
protector” connects mitochondrial volume regulation and metabo-
lism via the mKATP channel. Despite a role for mKATP in both physio-
logical and pathological conditions, the underlying molecular
structure of this channel and why it is evolutionarily conserved
remains unknown. Since the phenomenon of the mKATP has been de-
scribed in a range of organisms from plants to mammals, comparativegenomics may yield promising candidates, as was recently applied to
the identiﬁcation of the mitochondrial calcium uniporter [203,204].
However, if the mKATP is composed of known mitochondrial compo-
nents (e.g. complex II) this approach may not be successful. Pharma-
cologic evidence has suggested that the channel is molecularly
related to the surface KATP, and while a signiﬁcant pharmacologic
overlap made this hypothesis attractive, model organism genomics
has shown that a Kir subunit is not necessary for mKATP channel activ-
ity or protection against stress [154]. On the other hand, complex II
(and other components in the super-complex) are implicated not
only in energy sensing but also mitochondrial K+ ﬂuxes.
Despite recent reports [148], the quest for the precise molecular
identity of the mKATP and the role of complex II in regulating it con-
tinue. In particular, although knockout mice for the mKATP candidate
gene ROMK are available, these mice exhibit renal pathology [205]
which could cloud interpretation of experiments on cardioprotection.
Clearly, a cardiac-speciﬁc ROMK−/− mouse would be a useful tool to
elucidate the role of ROMK in cardioprotection. Furthermore, newly
discovered inhibitors or activators of ROMK and other members of
the inward rectifying K+ channel family [206] will be useful tools,
and (in the case of activators) potential therapeutics.
Although the complete loss of complex II in mammalian models is
lethal [207], the generation of inducible tissue-speciﬁc knockout
models may provide the tools necessary to address the role of complex
II in cytoprotection. In such models, an acute loss of complex II activity
in adulthood would be necessary, to avoid the contribution of develop-
mental andmetabolic affects associated with long term loss of function.
Alternatively, microRNA regulation of complex II (e.g., by miR-210
[208]) may be a promising avenue to inﬂuence complex II levels, and
is worthy of pursuit not only from a mechanistic angle, but also due
to the increasing interest in miRNAs as therapeutic targets.
Finally, although complex II inhibitors are prevalent (Table 2), there is
currently only one allosteric activator of complex II activity, namely ATP.
Clearly such activators could have both therapeutic and investigational
value, and the search for more such molecules should be encouraged.
Acknowledgements
This work was supported by an American Heart Association
Founder's Afﬁliate Postdoctoral Fellowship award 11POST7290028 (to
A.P.W.), and by US National Institutes of Health grants HL071158 (to
P.S.B.), GM087483 (to P.S.B. & K.W.N.).
References
[1] F. Sun, X. Huo, Y. Zhai, A. Wang, J. Xu, D. Su, M. Bartlam, Z. Rao, Crystal structure
of mitochondrial respiratory membrane protein complex II, Cell 121 (2005)
1043–1057.
607A.P. Wojtovich et al. / Biochimica et Biophysica Acta 1827 (2013) 598–611[2] C. Hagerhall, Succinate: quinone oxidoreductases. Variations on a conserved
theme, Biochim. Biophys. Acta 1320 (1997) 107–141.
[3] I.E. Schefﬂer, Molecular genetics of succinate:quinone oxidoreductase in eukaryotes,
Prog. Nucleic Acid Res. Mol. Biol. 60 (1998) 267–315.
[4] G. Cecchini, Function and structure of complex II of the respiratory chain, Annu.
Rev. Biochem. 72 (2003) 77–109.
[5] G. Lenaz, M.L. Genova, Structure and organization of mitochondrial respiratory
complexes: a new understanding of an old subject, Antioxid. Redox Signal. 12
(2010) 961–1008.
[6] P. Rustin, A. Munnich, A. Rotig, Succinate dehydrogenase and human
diseases: new insights into a well-known enzyme, Eur. J. Hum. Genet. 10
(2002) 289–291.
[7] L. Ernster, G. Dallner, Biochemical, physiological and medical aspects of ubiquinone
function, Biochim. Biophys. Acta 1271 (1995) 195–204.
[8] S. Niemann, U. Muller, Mutations in SDHC cause autosomal dominant
paraganglioma, type 3, Nat. Genet. 26 (2000) 268–270.
[9] B.E. Baysal, R.E. Ferrell, J.E. Willett-Brozick, E.C. Lawrence, D. Myssiorek, A. Bosch,
M.A. van der, P.E. Taschner, W.S. Rubinstein, E.N. Myers, C.W. Richard, C.J.
Cornelisse III, P. Devilee, B. Devlin, Mutations in SDHD, a mitochondrial complex
II gene, in hereditary paraganglioma, Science 287 (2000) 848–851.
[10] D. Astuti, F. Latif, A. Dallol, P.L. Dahia, F. Douglas, E. George, F. Skoldberg, E.S.
Husebye, C. Eng, E.R. Maher, Gene mutations in the succinate dehydrogenase
subunit SDHB cause susceptibility to familial pheochromocytoma and to familial
paraganglioma, Am. J. Hum. Genet. 69 (2001) 49–54.
[11] A.P. Gimenez-Roqueplo, J. Favier, P. Rustin, J.J. Mourad, P.F. Plouin, P. Corvol, A.
Rotig, X. Jeunemaitre, The R22X mutation of the SDHD gene in hereditary
paraganglioma abolishes the enzymatic activity of complex II in the mitochondrial
respiratory chain and activates the hypoxia pathway, Am. J. Hum. Genet. 69 (2001)
1186–1197.
[12] H.X. Hao, O. Khalimonchuk, M. Schraders, N. Dephoure, J.P. Bayley, H. Kunst, P.
Devilee, C.W. Cremers, J.D. Schiffman, B.G. Bentz, S.P. Gygi, D.R. Winge, H. Kremer,
J. Rutter, SDH5, a gene required for ﬂavination of succinate dehydrogenase, is
mutated in paraganglioma, Science 325 (2009) 1139–1142.
[13] B.E. Baysal, W.S. Rubinstein, P.E. Taschner, Phenotypic dichotomy inmitochondrial
complex II genetic disorders, J. Mol. Med. (Berl.) 79 (2001) 495–503.
[14] J. Favier, J.J. Briere, N. Burnichon, J. Riviere, L. Vescovo, P. Benit, I. Giscos-Douriez,
R.A. De, J. Bertherat, C. Badoual, F. Tissier, L. Amar, R. Libe, P.F. Plouin, X.
Jeunemaitre, P. Rustin, A.P. Gimenez-Roqueplo, The Warburg effect is genetically
determined in inherited pheochromocytomas, PLoS One 4 (2009) e7094.
[15] E. Holme, A kinetic study of thymine 7-hydroxylase from neurospora crassa,
Biochemistry 14 (1975) 4999–5003.
[16] R. Myllyla, L. Tuderman, K.I. Kivirikko, Mechanism of the prolyl hydroxylase re-
action. 2. Kinetic analysis of the reaction sequence, Eur. J. Biochem. 80 (1977)
349–357.
[17] E.D. MacKenzie, M.A. Selak, D.A. Tennant, L.J. Payne, S. Crosby, C.M. Frederiksen,
D.G. Watson, E. Gottlieb, Cell-permeating alpha-ketoglutarate derivatives allevi-
ate pseudohypoxia in succinate dehydrogenase-deﬁcient cells, Mol. Cell. Biol. 27
(2007) 3282–3289.
[18] C.J. Schoﬁeld, Z. Zhang, Structural and mechanistic studies on 2-oxoglutarate-
dependent oxygenases and related enzymes, Curr. Opin. Struct. Biol. 9 (1999)
722–731.
[19] W.G. Kaelin Jr., The von Hippel-Lindau tumour suppressor protein: O2 sensing
and cancer, Nat. Rev. Cancer 8 (2008) 865–873.
[20] W.G. Kaelin Jr., P.J. Ratcliffe, Oxygen sensing by metazoans: the central role of
the HIF hydroxylase pathway, Mol. Cell 30 (2008) 393–402.
[21] J.J. Briere, J. Favier, P. Benit, G. El, V.A. Lorenzato, D. Rabier, M.F. Di Renzo, A.P.
Gimenez-Roqueplo, P. Rustin, Mitochondrial succinate is instrumental for
HIF1alpha nuclear translocation in SDHA-mutant ﬁbroblasts under normoxic
conditions, Hum. Mol. Genet. 14 (2005) 3263–3269.
[22] A.P. Gimenez-Roqueplo, J. Favier, P. Rustin, C. Rieubland, V. Kerlan, P.F. Plouin, A.
Rotig, X. Jeunemaitre, Functional consequences of a SDHB gene mutation in an
apparently sporadic pheochromocytoma, J. Clin. Endocrinol. Metab. 87 (2002)
4771–4774.
[23] P.J. Pollard, J.J. Briere, N.A. Alam, J. Barwell, E. Barclay, N.C. Wortham, T. Hunt, M.
Mitchell, S. Olpin, S.J. Moat, I.P. Hargreaves, S.J. Heales, Y.L. Chung, J.R. Grifﬁths,
A. Dalgleish, J.A. McGrath, M.J. Gleeson, S.V. Hodgson, R. Poulsom, P. Rustin, I.P.
Tomlinson, Accumulation of Krebs cycle intermediates and over-expression of
HIF1alpha in tumours which result from germline FH and SDH mutations,
Hum. Mol. Genet. 14 (2005) 2231–2239.
[24] B.E. Baysal, On the association of succinate dehydrogenase mutations with
hereditary paraganglioma, Trends Endocrinol. Metab. 14 (2003) 453–459.
[25] P.J. Pollard, N.C. Wortham, I.P. Tomlinson, The TCA cycle and tumorigenesis: the
examples of fumarate hydratase and succinate dehydrogenase, Ann. Med. 35
(2003) 632–639.
[26] N. Raimundo, B.E. Baysal, G.S. Shadel, Revisiting the TCA cycle: signaling to
tumor formation, Trends Mol. Med. 17 (2011) 641–649.
[27] S.J. Ralph, R. Moreno-Sanchez, J. Neuzil, S. Rodriguez-Enriquez, Inhibitors of
succinate: quinone reductase/Complex II regulate production of mitochondrial
reactive oxygen species and protect normal cells from ischemic damage but
induce speciﬁc cancer cell death, Pharm. Res. 28 (2011) 2695–2730.
[28] C. Bardella, P.J. Pollard, I. Tomlinson, SDH mutations in cancer, Biochim. Biophys.
Acta 1807 (2011) 1432–1443.
[29] Y. Ni, X. He, J. Chen, J. Moline, J. Mester, M.S. Orloff, M.D. Ringel, C. Eng, Germline
SDHx variants modify breast and thyroid cancer risks in Cowden and
Cowden-like syndrome via FAD/NAD-dependant destabilization of p53, Hum.
Mol. Genet. 21 (2012) 300–310.[30] S.J. Yeung, J. Pan, M.H. Lee, Roles of p53, MYC and HIF-1 in regulating glycolysis—
the seventh hallmark of cancer, Cell. Mol. Life Sci. 65 (2008) 3981–3999.
[31] K. Bensaad, K.H. Vousden, p53: new roles in metabolism, Trends Cell Biol. 17
(2007) 286–291.
[32] M.P. Murphy, How mitochondria produce reactive oxygen species, Biochem. J.
417 (2009) 1–13.
[33] R. Paddenberg, B. Ishaq, A. Goldenberg, P. Faulhammer, F. Rose, N. Weissmann,
R.C. Braun-Dullaeus, W. Kummer, Essential role of complex II of the respiratory
chain in hypoxia-induced ROS generation in the pulmonary vasculature, Am. J.
Physiol. Lung Cell. Mol. Physiol. 284 (2003) L710–L719.
[34] V. Yankovskaya, R. Horseﬁeld, S. Tornroth, C. Luna-Chavez, H. Miyoshi, C. Leger,
B. Byrne, G. Cecchini, S. Iwata, Architecture of succinate dehydrogenase and re-
active oxygen species generation, Science 299 (2003) 700–704.
[35] E.H. Smith, R. Janknecht, L.J. Maher III, Succinate inhibition of alpha-
ketoglutarate-dependent enzymes in a yeast model of paraganglioma, Hum.
Mol. Genet. 16 (2007) 3136–3148.
[36] P. Goffrini, T. Ercolino, E. Panizza, V. Giache, L. Cavone, A. Chiarugi, V. Dima, I.
Ferrero, M. Mannelli, Functional study in a yeast model of a novel succinate de-
hydrogenase subunit B gene germline missense mutation (C191Y) diagnosed in
a patient affected by a glomus tumor, Hum. Mol. Genet. 18 (2009) 1860–1868.
[37] S.S. Szeto, S.N. Reinke, B.D. Sykes, B.D. Lemire, Ubiquinone-binding site muta-
tions in the Saccharomyces cerevisiae succinate dehydrogenase generate super-
oxide and lead to the accumulation of succinate, J. Biol. Chem. 282 (2007)
27518–27526.
[38] S.S. Szeto, S.N. Reinke, B.D. Sykes, B.D. Lemire, Ubiquinone-binding site muta-
tions in the Saccharomyces cerevisiae succinate dehydrogenase generate super-
oxide and lead to the accumulation of succinate, J. Biol. Chem. 282 (2007)
27518–27526.
[39] H. Adachi, Y. Fujiwara, N. Ishii, Effects of oxygen on protein carbonyl and aging
in Caenorhabditis elegans mutants with long (age-1) and short (mev-1) life
spans, J. Gerontol. A Biol. Sci. Med. Sci. 53 (1998) B240–B244.
[40] T. Ishii, K. Yasuda, A. Akatsuka, O. Hino, P.S. Hartman, N. Ishii, A mutation in the
SDHC gene of complex II increases oxidative stress, resulting in apoptosis and
tumorigenesis, Cancer Res. 65 (2005) 203–209.
[41] R.D. Guzy, B. Sharma, E. Bell, N.S. Chandel, P.T. Schumacker, Loss of the SdhB, but
Not the SdhA, subunit of complex II triggers reactive oxygen species-dependent
hypoxia-inducible factor activation and tumorigenesis, Mol. Cell. Biol. 28 (2008)
718–731.
[42] A.M. Cervera, N. Apostolova, F.L. Crespo, M. Mata, K.J. McCreath, Cells silenced
for SDHB expression display characteristic features of the tumor phenotype,
Cancer Res. 68 (2008) 4058–4067.
[43] M. Brownlee, A radical explanation for glucose-induced beta cell dysfunction,
J. Clin. Invest. 112 (2003) 1788–1790.
[44] K. Green, M.D. Brand, M.P. Murphy, Prevention of mitochondrial oxidative dam-
age as a therapeutic strategy in diabetes, Diabetes 53 (Suppl. 1) (2004)
S110–S118.
[45] J.A. Herlein, B.D. Fink, W.I. Sivitz, Superoxide production by mitochondria of
insulin-sensitive tissues: mechanistic differences and effect of early diabetes,
Metabolism 59 (2010) 247–257.
[46] W. He, F.J. Miao, D.C. Lin, R.T. Schwandner, Z. Wang, J. Gao, J.L. Chen, H. Tian, L.
Ling, Citric acid cycle intermediates as ligands for orphan G-protein-coupled re-
ceptors, Nature 429 (2004) 188–193.
[47] L.A. Fahien, M.J. MacDonald, The succinate mechanism of insulin release, Diabe-
tes 51 (2002) 2669–2676.
[48] T.S. Park, H. Yamashita, W.S. Blaner, I.J. Goldberg, Lipids in the heart: a source of
fuel and a source of toxins, Curr. Opin. Lipidol. 18 (2007) 277–282.
[49] J.G. Duncan, J.L. Fong, D.M. Medeiros, B.N. Finck, D.P. Kelly, Insulin-resistant
heart exhibits a mitochondrial biogenic response driven by the peroxisome
proliferator-activated receptor-alpha/PGC-1alpha gene regulatory pathway,
Circulation 115 (2007) 909–917.
[50] J.A. Herlein, B.D. Fink, D.M. Henry, M.A. Yorek, L.M. Teesch, W.I. Sivitz, Mitochon-
drial superoxide and coenzyme Q in insulin-deﬁcient rats: increased electron
leak, Am. J. Physiol. Regul. Integr. Comp. Physiol. 301 (2011) R1616–R1624.
[51] M.D. Brand, The sites and topology of mitochondrial superoxide production,
Exp. Gerontol. 45 (2010) 466–472.
[52] M. Gutman, Modulation of mitochondrial succinate-dehydrogenase activity,
mechanism and function, Mol. Cell. Biochem. 20 (1978) 41–60.
[53] L. Ernster, G. Dallner, Biochemical, physiological and medical aspects of ubiqui-
none function, Biochim. Biophys. Acta 1271 (1995) 195–204.
[54] P. Rustin, A. Rotig, Inborn errors of complex II—unusual human mitochondrial
diseases, Biochim. Biophys. Acta 1553 (2002) 117–122.
[55] T. Bourgeron, P. Rustin, D. Chretien, M. Birch-Machin, M. Bourgeois, E.
Viegas-Pequignot, A. Munnich, A. Rotig, Mutation of a nuclear succinate dehy-
drogenase gene results in mitochondrial respiratory chain deﬁciency, Nat.
Genet. 11 (1995) 144–149.
[56] M. Pandey, K.P. Mohanakumar, R. Usha, Mitochondrial functional alterations in
relation to pathophysiology of Huntington's disease, J. Bioenerg. Biomembr. 42
(2010) 217–226.
[57] F.O. Walker, Huntington's disease, Lancet 369 (2007) 218–228.
[58] M. Gu, M.T. Gash, V.M. Mann, F. Javoy-Agid, J.M. Cooper, A.H. Schapira,
Mitochondrial defect in Huntington's disease caudate nucleus, Ann. Neurol. 39
(1996) 385–389.
[59] S.E. Browne, A.C. Bowling, U. MacGarvey, M.J. Baik, S.C. Berger, M.M. Muqit, E.D.
Bird, M.F. Beal, Oxidative damage and metabolic dysfunction in Huntington's
disease: selective vulnerability of the basal ganglia, Ann. Neurol. 41 (1997)
646–653.
608 A.P. Wojtovich et al. / Biochimica et Biophysica Acta 1827 (2013) 598–611[60] A. Benchoua, Y. Trioulier, D. Zala, M.C. Gaillard, N. Lefort, N. Dufour, F. Saudou,
J.M. Elalouf, E. Hirsch, P. Hantraye, N. Deglon, E. Brouillet, Involvement of
mitochondrial complex II defects in neuronal death produced by N-terminus
fragment of mutated huntingtin, Mol. Biol. Cell 17 (2006) 1652–1663.
[61] A. Johri, M.F. Beal, Antioxidants in Huntington's disease, Biochim. Biophys. Acta
1822 (2012) 664–674.
[62] M.F. Beal, E. Brouillet, B. Jenkins, R. Henshaw, B. Rosen, B.T. Hyman,
Age-dependent striatal excitotoxic lesions produced by the endogenous mito-
chondrial inhibitor malonate, J. Neurochem. 61 (1993) 1147–1150.
[63] C.V. Borlongan, T.K. Koutouzis, P.R. Sanberg, 3-Nitropropionic acid animal model
and Huntington's disease, Neurosci. Biobehav. Rev. 21 (1997) 289–293.
[64] P. Kamoun, M.C. Belardinelli, A. Chabli, K. Lallouchi, B. Chadefaux-Vekemans,
Endogenous hydrogen sulﬁde overproduction in Down syndrome, Am. J. Med.
Genet. A 116A (2003) 310–311.
[65] A.A. Khan, M.M. Schuler, M.G. Prior, S. Yong, R.W. Coppock, L.Z. Florence, L.E.
Lillie, Effects of hydrogen sulﬁde exposure on lung mitochondrial respiratory
chain enzymes in rats, Toxicol. Appl. Pharmacol. 103 (1990) 482–490.
[66] P. Kamoun, Mental retardation in Down syndrome: a hydrogen sulﬁde hypoth-
esis, Med. Hypotheses 57 (2001) 389–392.
[67] D. Gems, R. Doonan, Antioxidant defense and aging in C. elegans: is the oxidative
damage theory of aging wrong? Cell Cycle 8 (2009) 1681–1687.
[68] R. Doonan, J.J. McElwee, F. Matthijssens, G.A. Walker, K. Houthoofd, P. Back, A.
Matscheski, J.R. Vanﬂeteren, D. Gems, Against the oxidative damage theory of
aging: superoxide dismutases protect against oxidative stress but have little or
no effect on life span in Caenorhabditis elegans, Genes Dev. 22 (2008)
3236–3241.
[69] F. Cabreiro, D. Ackerman, R. Doonan, C. Araiz, P. Back, D. Papp, B.P. Braeckman, D.
Gems, Increased life span from overexpression of superoxide dismutase in
Caenorhabditis elegans is not caused by decreased oxidative damage, Free
Radic. Biol. Med. 51 (2011) 1575–1582.
[70] Y. Zhang, Y. Ikeno, W. Qi, A. Chaudhuri, Y. Li, A. Bokov, S.R. Thorpe, J.W. Baynes,
C. Epstein, A. Richardson, R.H. Van, Mice deﬁcient in both Mn superoxide
dismutase and glutathione peroxidase-1 have increased oxidative damage and
a greater incidence of pathology but no reduction in longevity, J. Gerontol. A
Biol. Sci. Med. Sci. 64 (2009) 1212–1220.
[71] B. Lakowski, S. Hekimi, Determination of life-span in Caenorhabditis elegans by
four clock genes, Science 272 (1996) 1010–1013.
[72] A. Dillin, A.L. Hsu, N. rantes-Oliveira, J. Lehrer-Graiwer, H. Hsin, A.G. Fraser, R.S.
Kamath, J. Ahringer, C. Kenyon, Rates of behavior and aging speciﬁed by
mitochondrial function during development, Science 298 (2002) 2398–2401.
[73] S.S. Lee, R.Y. Lee, A.G. Fraser, R.S. Kamath, J. Ahringer, G. Ruvkun, A systematic
RNAi screen identiﬁes a critical role for mitochondria in C. elegans longevity,
Nat. Genet. 33 (2003) 40–48.
[74] B.G. Hughes, S. Hekimi, A mild impairment of mitochondrial electron transport
has sex-speciﬁc effects on lifespan and aging in mice, PLoS One 6 (2011) e26116.
[75] C. Dell'agnello, S. Leo, A. Agostino, G. Szabadkai, C. Tiveron, A. Zulian, A. Prelle, P.
Roubertoux, R. Rizzuto, M. Zeviani, Increased longevity and refractoriness to
Ca(2+)-dependent neurodegeneration in Surf1 knockout mice, Hum. Mol.
Genet. 16 (2007) 431–444.
[76] C.J. Kenyon, The genetics of ageing, Nature 464 (2010) 504–512.
[77] Y.Y. Yang, V. Vasta, S. Hahn, J.A. Gangoiti, E. Opheim, M.M. Sedensky, P.G.
Morgan, The role of DMQ(9) in the long-lived mutant clk-1, Mech. Ageing
Dev. 132 (2011) 331–339.
[78] W. Yang, S. Hekimi, Two modes of mitochondrial dysfunction lead independent-
ly to lifespan extension in Caenorhabditis elegans, Aging Cell 9 (2010) 433–447.
[79] R. Mehta, K.A. Steinkraus, G.L. Sutphin, F.J. Ramos, L.S. Shamieh, A. Huh, C. Davis,
D. Chandler-Brown, M. Kaeberlein, Proteasomal regulation of the hypoxic
response modulates aging in C. elegans, Science 324 (2009) 1196–1198.
[80] S.J. Lee, A.B. Hwang, C. Kenyon, Inhibition of respiration extends C. elegans life
span via reactive oxygen species that increase HIF-1 activity, Curr. Biol. 20
(2010) 2131–2136.
[81] J. Durieux, S. Wolff, A. Dillin, The cell-non-autonomous nature of electron trans-
port chain-mediated longevity, Cell 144 (2011) 79–91.
[82] L. Walter, A. Baruah, H.W. Chang, H.M. Pace, S.S. Lee, The homeobox protein
CEH-23 mediates prolonged longevity in response to impaired mitochondrial
electron transport chain in C. elegans, PLoS Biol. 9 (2011) e1001084.
[83] B.M. Baker, A.M. Nargund, T. Sun, C.M. Haynes, Protective coupling of mitochon-
drial function and protein synthesis via the eIF2alpha kinase GCN-2, PLoS Genet.
8 (2012) e1002760.
[84] A.M. Nargund, M.W. Pellegrino, C.J. Fiorese, B.M. Baker, C.M. Haynes, Mitochon-
drial import efﬁciency of ATFS-1 regulates mitochondrial UPR activation,
Science 337 (2012) 587–590.
[85] N. Ishii, M. Fujii, P.S. Hartman, M. Tsuda, K. Yasuda, N. Senoo-Matsuda, S.
Yanase, D. Ayusawa, K. Suzuki, A mutation in succinate dehydrogenase
cytochrome b causes oxidative stress and ageing in nematodes, Nature 394
(1998) 694–697.
[86] J. Huang, B.D. Lemire, Mutations in the C. elegans succinate dehydrogenase iron–
sulfur subunit promote superoxide generation and premature aging, J. Mol. Biol.
387 (2009) 559–569.
[87] M. Tsuda, T. Sugiura, T. Ishii, N. Ishii, T. Aigaki, A mev-1-like dominant-negative
SdhC increases oxidative stress and reduces lifespan in Drosophila, Biochem.
Biophys. Res. Commun. 363 (2007) 342–346.
[88] T. Ishii, M. Miyazawa, A. Onodera, K. Yasuda, N. Kawabe, M. Kirinashizawa, S.
Yoshimura, N. Maruyama, P.S. Hartman, N. Ishii, Mitochondrial reactive oxygen
species generation by the SDHC V69E mutation causes low birth weight and
neonatal growth retardation, Mitochondrion 11 (2011) 155–165.[89] J.A. Butler, N. Ventura, T.E. Johnson, S.L. Rea, Long-lived mitochondrial (Mit)
mutants of Caenorhabditis elegans utilize a novel metabolism, FASEB J. 24
(2010) 4977–4988.
[90] M. Pfeiffer, E.B. Kayzer, X. Yang, E. Abramson, M.A. Kenaston, C.U. Lago, H.H. Lo,
M.M. Sedensky, A. Lunceford, C.F. Clarke, S.J. Wu, C. McLeod, T. Finkel, P.G.
Morgan, E.M. Mills, Caenorhabditis elegans UCP4 protein controls complex
II-mediated oxidative phosphorylation through succinate transport, J. Biol.
Chem. 286 (2011) 37712–37720.
[91] S.S. Ali, M. Hsiao, H.W. Zhao, L.L. Dugan, G.G. Haddad, D. Zhou, Hypoxia-
adaptation involves mitochondrial metabolic depression and decreased ROS
leakage, PLoS One 7 (2012) e36801.
[92] J.R. Hom, R.A. Quintanilla, D.L. Hoffman, K.L. de Mesy Bentley, J.D. Molkentin, S.S.
Sheu, G.A. Porter Jr., The permeability transition pore controls cardiac mitochon-
drial maturation and myocyte differentiation, Dev. Cell 21 (2011) 469–478.
[93] E. Murphy, C. Steenbergen, Mechanisms underlying acute protection from cardi-
ac ischemia–reperfusion injury, Physiol. Rev. 88 (2008) 581–609.
[94] C.E. Murry, R.B. Jennings, K.A. Reimer, Preconditioning with ischemia: a delay of
lethal cell injury in ischemic myocardium, Circulation 74 (1986) 1124–1136.
[95] A.P. Halestrap, S.J. Clarke, I. Khaliulin, The role of mitochondria in protection of
the heart by preconditioning, Biochim. Biophys. Acta 1767 (2007) 1007–1031.
[96] E. Murphy, C. Steenbergen, Preconditioning: the mitochondrial connection,
Annu. Rev. Physiol. 69 (2007) 51–67.
[97] L.S. Burwell, S.M. Nadtochiy, P.S. Brookes, Cardioprotection by metabolic
shut-down and gradual wake-up, J. Mol. Cell. Cardiol. 46 (2009) 804–810.
[98] C.P. Baines, M. Goto, J.M. Downey, Oxygen radicals released during ischemic
preconditioning contribute to cardioprotection in the rabbit myocardium,
J. Mol. Cell. Cardiol. 29 (1997) 207–216.
[99] G. Valen, J. Starkopf, S. Takeshima, T. Kullisaar, T. Vihalemm, A.T. Kengsepp, C.
Lowbeer, J. Vaage, M. Zilmer, Preconditioning with hydrogen peroxide (H2O2)
or ischemia in H2O2-induced cardiac dysfunction, Free Radic. Res. 29 (1998)
235–245.
[100] T.L. Vanden Hoek, L.B. Becker, Z. Shao, C. Li, P.T. Schumacker, Reactive oxygen spe-
cies released from mitochondria during brief hypoxia induce preconditioning in
cardiomyocytes, J. Biol. Chem. 273 (1998) 18092–18098.
[101] P. Pasdois, B. Beauvoit, L. Tariosse, B. Vinassa, S. Bonoron-Adele, P.D. Santos,
MitoK(ATP)-dependent changes in mitochondrial volume and in complex II
activity during ischemic and pharmacological preconditioning of Langendorff-
perfused rat heart, J. Bioenerg. Biomembr. 38 (2006) 101–112.
[102] A.P. Wojtovich, P.S. Brookes, The endogenous mitochondrial complex II inhibitor
malonate regulates mitochondrial ATP-sensitive potassium channels: Implications
for ischemic preconditioning, Biochim. Biophys. Acta 1777 (2008) 882–889.
[103] N.I. Fedotcheva, A.P. Sokolov, M.N. Kondrashova, Nonezymatic formation of succi-
nate in mitochondria under oxidative stress, Free Radic. Biol. Med. 41 (2006) 56–64.
[104] A.P. Wojtovich, P.S. Brookes, The complex II inhibitor atpenin A5 protects
against cardiac ischemia-reperfusion injury via activation of mitochondrial
KATP channels, Basic Res. Cardiol. 104 (2009) 121–129.
[105] Y.S. Kim, Malonate metabolism: biochemistry, molecular biology, physiology,
and industrial application, J. Biochem. Mol. Biol. 35 (2002) 443–451.
[106] S.M. Nadtochiy, P.R. Baker, B.A. Freeman, P.S. Brookes, Mitochondrial nitroalkene
formation and mild uncoupling in ischaemic preconditioning: implications for
cardioprotection, Cardiovasc. Res. 82 (2009) 333–340.
[107] F.J. Schopfer, C. Batthyany, P.R. Baker, G. Bonacci, M.P. Cole, V. Rudolph, A.L.
Groeger, T.K. Rudolph, S. Nadtochiy, P.S. Brookes, B.A. Freeman, Detection and
quantiﬁcation of protein adduction by electrophilic fatty acids: mitochondrial
generation of fatty acid nitroalkene derivatives, Free Radic. Biol. Med. 46
(2009) 1250–1259.
[108] B.B. Queliconi, A.P. Wojtovich, S.M. Nadtochiy, A.J. Kowaltowski, P.S. Brookes,
Redox regulation of the mitochondrial K(ATP) channel in cardioprotection,
Biochim. Biophys. Acta 1813 (2011) 1309–1315.
[109] S. Shiva, J.H. Crawford, A. Ramachandran, E.K. Ceaser, T. Hillson, P.S. Brookes, R.P.
Patel, V.M. Darley-Usmar, Mechanisms of the interaction of nitroxyl with mito-
chondria, Biochem. J. 379 (2004) 359–366.
[110] P. Pagliaro, D. Mancardi, R. Rastaldo, C. Penna, D. Gattullo, K.M. Miranda, M.
Feelisch, D.A. Wink, D.A. Kass, N. Paolocci, Nitroxyl affords thiol-sensitive
myocardial protective effects akin to early preconditioning, Free Radic. Biol.
Med. 34 (2003) 33–43.
[111] Y.R. Chen, C.L. Chen, D.R. Pfeiffer, J.L. Zweier, Mitochondrial complex II in the
post-ischemic heart: oxidative injury and the role of protein S-glutathionylation,
J. Biol. Chem. 282 (2007) 32640–32654.
[112] M.W. Riepe, F. Esclaire, K. Kasischke, S. Schreiber, H. Nakase, O. Kempski, A.C.
Ludolph, U. Dirnagl, J. Hugon, Increased hypoxic tolerance by chemical inhibi-
tion of oxidative phosphorylation: “chemical preconditioning”, J. Cereb. Blood
Flow Metab. 17 (1997) 257–264.
[113] R.A. Ockaili, P. Bhargava, R.C. Kukreja, Chemical preconditioning with
3-nitropropionic acid in hearts: role of mitochondrial K(ATP) channel, Am. J.
Physiol. Heart Circ. Physiol. 280 (2001) H2406–H2411.
[114] H. Miyadera, K. Shiomi, H. Ui, Y. Yamaguchi, R. Masuma, H. Tomoda, H. Miyoshi,
A. Osanai, K. Kita, S. Omura, Atpenins, potent and speciﬁc inhibitors of mito-
chondrial complex II (succinate-ubiquinone oxidoreductase), Proc. Natl. Acad.
Sci. U. S. A. 100 (2003) 473–477.
[115] K.D. Garlid, P. Paucek, V. Yarov-Yarovoy, H.N. Murray, R.B. Darbenzio, A.J.
D'Alonzo, N.J. Lodge, M.A. Smith, G.J. Grover, Cardioprotective effect of diazoxide
and its interaction with mitochondrial ATP-sensitive K+ channels. Possible
mechanism of cardioprotection, Circ. Res. 81 (1997) 1072–1082.
[116] T. Mizumura, K. Nithipatikom, G.J. Gross, Bimakalim, an ATP-sensitive potassium
channel opener, mimics the effects of ischemic preconditioning to reduce infarct
609A.P. Wojtovich et al. / Biochimica et Biophysica Acta 1827 (2013) 598–611size, adenosine release, and neutrophil function in dogs, Circulation 92 (1995)
1236–1245.
[117] J.A. Auchampach, G.J. Grover, G.J. Gross, Blockade of ischaemic preconditioning
in dogs by the novel ATP dependent potassium channel antagonist sodium
5-hydroxydecanoate, Cardiovasc. Res. 26 (1992) 1054–1062.
[118] G.J. Gross, J.A. Auchampach, Blockade of ATP-sensitive potassium channels pre-
vents myocardial preconditioning in dogs, Circ. Res. 70 (1992) 223–233.
[119] E.J. Hide, C. Thiemermann, Limitation of myocardial infarct size in the rabbit by
ischaemic preconditioning is abolished by sodium 5-hydroxydecanoate,
Cardiovasc. Res. 31 (1996) 941–946.
[120] K.D. Garlid, P. Paucek, Mitochondrial potassium transport: the K(+) cycle,
Biochim. Biophys. Acta 1606 (2003) 23–41.
[121] A.P. Halestrap, The regulation of the matrix volume of mammalian mitochondria
in vivo and in vitro and its role in the control of mitochondrial metabolism,
Biochim. Biophys. Acta 973 (1989) 355–382.
[122] A.D. Costa, C.L. Quinlan, A. Andrukhiv, I.C. West, M. Jaburek, K.D. Garlid, The
direct physiological effects of mitoK(ATP) opening on heart mitochondria, Am.
J. Physiol. Heart Circ. Physiol. 290 (2006) H406–H415.
[123] M.M. da Silva, A. Sartori, E. Belisle, A.J. Kowaltowski, Ischemic preconditioning
inhibits mitochondrial respiration, increases H2O2 release, and enhances K+
transport, Am. J. Physiol. Heart Circ. Physiol. 285 (2003) H154–H162.
[124] H. Hibino, A. Inanobe, K. Furutani, S. Murakami, I. Findlay, Y. Kurachi, Inwardly
rectifying potassium channels: their structure, function, and physiological
roles, Physiol. Rev. 90 (2010) 291–366.
[125] I. Inoue, H. Nagase, K. Kishi, T. Higuti, ATP-sensitive K+ channel in the mito-
chondrial inner membrane, Nature 352 (1991) 244–247.
[126] D.J. Pagliarini, S.E. Calvo, B. Chang, S.A. Sheth, S.B. Vafai, S.E. Ong, G.A. Walford, C.
Sugiana, A. Boneh, W.K. Chen, D.E. Hill, M. Vidal, J.G. Evans, D.R. Thorburn, S.A.
Carr, V.K. Mootha, A mitochondrial protein compendium elucidates complex I
disease biology, Cell 134 (2008) 112–123.
[127] C. Guda, P. Guda, E. Fahy, S. Subramaniam, MITOPRED: a web server for the pre-
diction of mitochondrial proteins, Nucleic Acids Res. 32 (2004) W372–W374.
[128] J. Balss, P. Papatheodorou, M. Mehmel, D. Baumeister, B. Hertel, N. Delaroque,
F.C. Chatelain, D.L. Minor Jr., J.L. Van Etten, J. Rassow, A. Moroni, G. Thiel, Trans-
membrane domain length of viral K+ channels is a signal for mitochondria
targeting, Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 12313–12318.
[129] H.K. Anandatheerthavarada, G. Biswas, J. Mullick, N.B. Sepuri, L. Otvos, D. Pain,
N.G. Avadhani, Dual targeting of cytochrome P4502B1 to endoplasmic reticulum
and mitochondria involves a novel signal activation by cyclic AMP-dependent
phosphorylation at ser128, EMBO J. 18 (1999) 5494–5504.
[130] M. Suzuki, K. Kotake, K. Fujikura, N. Inagaki, T. Suzuki, T. Gonoi, S. Seino, K.
Takata, Kir6.1: a possible subunit of ATP-sensitive K+ channels in mitochondria,
Biochem. Biophys. Res. Commun. 241 (1997) 693–697.
[131] M. Zhou, O. Tanaka, M. Sekiguchi, K. Sakabe, M. Anzai, I. Izumida, T. Inoue, K.
Kawahara, H. Abe, Localization of the ATP-sensitive potassium channel subunit
(Kir6. 1/uK(ATP)-1) in rat brain, Brain Res. Mol. Brain Res. 74 (1999) 15–25.
[132] M. Zhou, H.J. He, R. Suzuki, O. Tanaka, M. Sekiguchi, Y. Yasuoka, K. Kawahara, H.
Itoh, H. Abe, Expression of ATP sensitive K+ channel subunit Kir6.1 in rat
kidney, Eur. J. Histochem. 51 (2007) 43–51.
[133] M.T. Jiang, M. Ljubkovic, Y. Nakae, Y. Shi, W.M. Kwok, D.F. Stowe, Z.J. Bosnjak,
Characterization of human cardiac mitochondrial ATP-sensitive potassium
channel and its regulation by phorbol ester in vitro, Am. J. Physiol. Heart Circ.
Physiol. 290 (2006) H1770–H1776.
[134] H. Singh, D. Hudman, C.L. Lawrence, R.D. Rainbow, D. Lodwick, R.I. Norman, Dis-
tribution of Kir6.0 and SUR2 ATP-sensitive potassium channel subunits in isolat-
ed ventricular myocytes, J. Mol. Cell. Cardiol. 35 (2003) 445–459.
[135] Z. Lacza, J.A. Snipes, A.W. Miller, C. Szabo, G. Grover, D.W. Busija, Heart mito-
chondria contain functional ATP-dependent K+ channels, J. Mol. Cell. Cardiol.
35 (2003) 1339–1347.
[136] Z. Lacza, J.A. Snipes, B. Kis, C. Szabo, G. Grover, D.W. Busija, Investigation of the
subunit composition and the pharmacology of the mitochondrial ATP-
dependent K+ channel in the brain, Brain Res. 994 (2003) 27–36.
[137] H. Ardehali, Z. Chen, Y. Ko, R. Mejia-Alvarez, E. Marban, Multiprotein complex
containing succinate dehydrogenase confers mitochondrial ATP-sensitive K+
channel activity, Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 11880–11885.
[138] D.B. Foster, J.J. Rucker, E. Marban, Is Kir6.1 a subunit of mitoK(ATP)? Biochem.
Biophys. Res. Commun. 366 (2008) 649–656.
[139] B. Ye, S.L. Kroboth, J.L. Pu, J.J. Sims, N.T. Aggarwal, E.M. McNally, J.C. Makielski,
N.Q. Shi, Molecular identiﬁcation and functional characterization of a mitochon-
drial sulfonylurea receptor 2 splice variant generated by intraexonic splicing,
Circ. Res. 105 (2009) 1083–1093.
[140] T. Miki, M. Suzuki, T. Shibasaki, H. Uemura, T. Sato, K. Yamaguchi, H. Koseki, T.
Iwanaga, H. Nakaya, S. Seino, Mouse model of Prinzmetal angina by disruption
of the inward rectiﬁer Kir6.1, Nat. Med. 8 (2002) 466–472.
[141] C. Shiota, O. Larsson, K.D. Shelton, M. Shiota, A.M. Efanov, M. Hoy, J. Lindner, S.
Kooptiwut, L. Juntti-Berggren, J. Gromada, P.O. Berggren, M.A. Magnuson, Sulfo-
nylurea receptor type 1 knock-out mice have intact feeding-stimulated insulin
secretion despite marked impairment in their response to glucose, J. Biol.
Chem. 277 (2002) 37176–37183.
[142] W.A. Chutkow, V. Samuel, P.A. Hansen, J. Pu, C.R. Valdivia, J.C. Makielski, C.F.
Burant, Disruption of Sur2-containing K(ATP) channels enhances insulin-
stimulated glucose uptake in skeletal muscle, Proc. Natl. Acad. Sci. U. S. A. 98
(2001) 11760–11764.
[143] W.A. Chutkow, J. Pu, M.T. Wheeler, T. Wada, J.C. Makielski, C.F. Burant, E.M.
McNally, Episodic coronary artery vasospasm and hypertension develop in the
absence of Sur2 K(ATP) channels, J. Clin. Invest. 110 (2002) 203–208.[144] J.R. Kersten, W.G. Toller, E.R. Gross, P.S. Pagel, D.C. Warltier, Diabetes abolishes
ischemic preconditioning: role of glucose, insulin, and osmolality, Am. J. Physiol.
Heart Circ. Physiol. 278 (2000) H1218–H1224.
[145] T. Miki, K. Nagashima, F. Tashiro, K. Kotake, H. Yoshitomi, A. Tamamoto, T. Gonoi, T.
Iwanaga, J. Miyazaki, S. Seino, Defective insulin secretion and enhanced insulin action
in KATP channel-deﬁcient mice, Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 10402–10406.
[146] M. Suzuki, N. Sasaki, T. Miki, N. Sakamoto, Y. Ohmoto-Sekine, M. Tamagawa, S.
Seino, E. Marban, H. Nakaya, Role of sarcolemmal K(ATP) channels in
cardioprotection against ischemia/reperfusion injury in mice, J. Clin. Invest.
109 (2002) 509–516.
[147] J. Seharaseyon, A. Ohler, N. Sasaki, H. Fraser, T. Sato, D.C. Johns, B. O'Rourke, E.
Marban, Molecular composition of mitochondrial ATP-sensitive potassium chan-
nels probed by viral Kir gene transfer, J. Mol. Cell. Cardiol. 32 (2000) 1923–1930.
[148] D.B. Foster, A.S. Ho, J. Rucker, A.O. Garlid, L. Chen, A. Sidor, K.D. Garlid, B.
O'Rourke, The mitochondrial ROMK channel is a molecular component of
MitoKATP, Circ. Res. 111 (2012) 446–454.
[149] C.M. McNicholas, Y. Yang, G. Giebisch, S.C. Hebert, Molecular site for nucleotide
binding on an ATP-sensitive renal K+ channel (ROMK2), Am. J. Physiol. 271
(1996) F275–F285.
[150] G.D. Mironova, A.E. Negoda, B.S. Marinov, P. Paucek, A.D. Costa, S.M. Grigoriev,
Y.Y. Skarga, K.D. Garlid, Functional distinctions between the mitochondrial
ATP-dependent K+ channel (mitoKATP) and its inward rectiﬁer subunit
(mitoKIR), J. Biol. Chem. 279 (2004) 32562–32568.
[151] A.P. Wojtovich, D.M. Williams, M.K. Karcz, C.M. Lopes, D.A. Gray, K.W. Nehrke,
P.S. Brookes, A novel mitochondrial KATP channel assay, Circ. Res. 106 (2010)
1190–1196.
[152] T. Kobayashi, K. Washiyama, K. Ikeda, Inhibition of G protein-activated inwardly
rectifying K+ channels by ﬂuoxetine (Prozac), Br. J. Pharmacol. 138 (2003)
1119–1128.
[153] T. Kobayashi, K. Washiyama, K. Ikeda, Modulators of G protein-activated in-
wardly rectifying K+ channels: potentially therapeutic agents for addictive
drug users, Ann. N. Y. Acad. Sci. 1025 (2004) 590–594.
[154] A.P. Wojtovich, P. DiStefano, T. Sherman, P.S. Brookes, K. Nehrke, Mitochondrial
ATP-sensitive potassium channel activity and hypoxic preconditioning are inde-
pendent of an inwardly rectifying potassium channel subunit in Caenorhabditis
elegans, FEBS Lett. 586 (2012) 428–434.
[155] A. Szewczyk, A. Kajma, D. Malinska, A. Wrzosek, P. Bednarczyk, B. Zablocka, K.
Dolowy, Pharmacology of mitochondrial potassium channels: dark side of the
ﬁeld, FEBS Lett. 584 (2010) 2063–2069.
[156] C.G. Nichols, KATP channels as molecular sensors of cellular metabolism, Nature
440 (2006) 470–476.
[157] A. Szewczyk, G. Wojcik, N.A. Lobanov, M.J. Nalecz, The mitochondrial sulfonyl-
urea receptor: identiﬁcation and characterization, Biochem. Biophys. Res.
Commun. 230 (1997) 611–615.
[158] R. Bajgar, S. Seetharaman, A.J. Kowaltowski, K.D. Garlid, P. Paucek, Identiﬁcation
and properties of a novel intracellular (mitochondrial) ATP-sensitive potassium
channel in brain, J. Biol. Chem. 276 (2001) 33369–33374.
[159] M. Jaburek, V. Yarov-Yarovoy, P. Paucek, K.D. Garlid, State-dependent inhibition
of the mitochondrial KATP channel by glyburide and 5-hydroxydecanoate,
J. Biol. Chem. 273 (1998) 13578–13582.
[160] A. Szewczyk, S. Pikula, G. Wojcik, M.J. Nalecz, Glibenclamide inhibits mitochon-
drial K+ and Na+ uniports induced by magnesium depletion, Int. J. Biochem.
Cell Biol. 28 (1996) 863–871.
[161] A. Ziemys, A. Toleikis, D.M. Kopustinskiene, Molecular modelling of K(ATP)
channel blockers-ADP/ATP carrier interactions, Syst. Biol. (Stevenage) 153
(2006) 390–393.
[162] M. Gutman, E.B. Kearney, T.P. Singer, Control of succinate dehydrogenase in mi-
tochondria, Biochemistry 10 (1971) 4763–4770.
[163] H. Schagger, K. Pfeiffer, Supercomplexes in the respiratory chains of yeast and
mammalian mitochondria, EMBO J. 19 (2000) 1777–1783.
[164] J.J. Briere, J. Favier, G. El, V.F. Djouadi, P. Benit, A.P. Gimenez, P. Rustin, Succinate
dehydrogenase deﬁciency in human, Cell. Mol. Life Sci. 62 (2005) 2317–2324.
[165] M. Comelli, G. Metelli, I. Mavelli, Downmodulation of mitochondrial F0F1 ATP
synthase by diazoxide in cardiac myoblasts: a dual effect of the drug, Am. J.
Physiol. Heart Circ. Physiol. 292 (2007) H820–H829.
[166] D.M. Kopustinskiene, A. Toleikis, N.E. Saris, Adenine nucleotide translocase me-
diates the K(ATP)-channel-openers-induced proton and potassium ﬂux to the
mitochondrial matrix, J. Bioenerg. Biomembr. 35 (2003) 141–148.
[167] A. Panov, S. Filippova, V. Lyakhovich, Adenine nucleotide translocase as a site of
regulation by ADP of the rat liver mitochondria permeability to H+ and K+
ions, Arch. Biochem. Biophys. 199 (1980) 420–426.
[168] A. Ziemys, A. Toleikis, D.M. Kopustinskiene, Molecular modelling of K(ATP)
channel blockers-ADP/ATP carrier interactions, Syst. Biol. (Stevenage) 153
(2006) 390–393.
[169] A.P. Wojtovich, K.W. Nehrke, P.S. Brookes, The mitochondrial complex II and
ATP-sensitive potassium channel interaction: quantitation of the channel in
heart mitochondria, Acta Biochim. Pol. 57 (2010) 431–434.
[170] P.P. Dzeja, P. Bast, C. Ozcan, A. Valverde, E.L. Holmuhamedov, D.G. Van Wylen, A.
Terzic, Targeting nucleotide-requiring enzymes: implications for diazoxide-
induced cardioprotection, Am. J. Physiol. Heart Circ. Physiol. 284 (2003)
H1048–H1056.
[171] G. Schafer, C. Wegener, R. Portenhauser, D. Bojanovski, Diazoxide, an inhibitor of
succinate oxidation, Biochem. Pharmacol. 18 (1969) 2678–2681.
[172] A.J. Kowaltowski, S. Seetharaman, P. Paucek, K.D. Garlid, Bioenergetic conse-
quences of opening the ATP-sensitive K(+) channel of heart mitochondria,
Am. J. Physiol. Heart Circ. Physiol. 280 (2001) H649–H657.
610 A.P. Wojtovich et al. / Biochimica et Biophysica Acta 1827 (2013) 598–611[173] C.L. Quinlan, A.L. Orr, I.V. Perevoshchikova, J.R. Treberg, B.A. Ackrell, M.D. Brand,
Mitochondrial complex II can generate reactive oxygen species at high rates in
both the forward and reverse reactions, J. Biol. Chem. 287 (2012) 27255–27264.
[174] S. Drose, L. Bleier, U. Brandt, A common mechanism links differently acting
complex II inhibitors to cardioprotection: modulation of mitochondrial reactive
oxygen species production, Mol. Pharmacol. 79 (2011) 814–822.
[175] M. Ksenzenko, A.A. Konstantinov, G.B. Khomutov, A.N. Tikhonov, E.K. Ruuge,
Effect of electron transfer inhibitors on superoxide generation in the
cytochrome bc1 site of the mitochondrial respiratory chain, FEBS Lett. 155
(1983) 19–24.
[176] M. Ksenzenko, A.A. Konstantinov, G.B. Khomutov, A.N. Tikhonov, E.K. Ruuge, Rela-
tionships between the effects of redox potential, alpha-thenoyltriﬂuoroacetone
and malonate on O(2) and H2O2 generation by submitochondrial particles in
the presence of succinate and antimycin, FEBS Lett. 175 (1984) 105–108.
[177] D. Malinska, S.R. Mirandola, W.S. Kunz, Mitochondrial potassium channels and
reactive oxygen species, FEBS Lett. 584 (2010) 2043–2048.
[178] S. Drose, P.J. Hanley, U. Brandt, Ambivalent effects of diazoxide on mitochondrial
ROS production at respiratory chain complexes I and III, Biochim. Biophys. Acta
1790 (2009) 558–565.
[179] H. Ardehali, B. O'Rourke, Mitochondrial K(ATP) channels in cell survival and
death, J. Mol. Cell. Cardiol. 39 (2005) 7–16.
[180] J.F. Turrens, A. Alexandre, A.L. Lehninger, Ubisemiquinone is the electron donor
for superoxide formation by complex III of heart mitochondria, Arch. Biochem.
Biophys. 237 (1985) 408–414.
[181] V. Guillet, N. Gueguen, R. Cartoni, A. Chevrollier, V. Desquiret, C. Angebault, P.
mati-Bonneau, V. Procaccio, D. Bonneau, J.C. Martinou, P. Reynier, Bioenergetic
defect associated with mKATP channel opening in a mouse model carrying a
mitofusin 2 mutation, FASEB J. 25 (2011) 1618–1627.
[182] H.T. Facundo, M. Fornazari, A.J. Kowaltowski, Tissue protection mediated by
mitochondrial K+ channels, Biochim. Biophys. Acta 1762 (2006) 202–212.
[183] A.D.T. Costa, M.A. Krieger, Evidence for an ATP-sensitive K+ channel in mitoplasts
isolated from Trypanosoma cruzi and Crithidia fasciculata, Int. J. Parasitol. 39 (2009)
955–961.
[184] A. Kicinska, A. Swida, P. Bednarczyk, I. Koszela-Piotrowska, K. Choma, K. Dolowy, A.
Szewczyk, W. Jarmuszkiewicz, ATP-sensitive potassium channel in mitochondria
of the eukaryotic microorganism Acanthamoeba castellanii, J. Biol. Chem. 282
(2007) 17433–17441.
[185] A.P. Wojtovich, L.S. Burwell, T.A. Sherman, K.W. Nehrke, P.S. Brookes, The C.
elegans mitochondrial K+(ATP) channel: a potential target for preconditioning,
Biochem. Biophys. Res. Commun. 376 (2008) 625–628.
[186] D. Pastore, M.C. Stoppelli, F.N. Di, S. Passarella, The existence of the K(+)
channel in plant mitochondria, J. Biol. Chem. 274 (1999) 26683–26690.
[187] C. Baltzer, S.K. Tiefenbock, C. Frei, Mitochondria in response to nutrients and
nutrient-sensitive pathways, Mitochondrion 10 (2010) 589–597.
[188] L.W. Finley, M.C. Haigis, Metabolic regulation by SIRT3: implications for tumori-
genesis, Trends Mol. Med. 18 (2012) 516–523.
[189] D.G. Hardie, F.A. Ross, S.A. Hawley, AMPK: a nutrient and energy sensor that
maintains energy homeostasis, Nat. Rev. Mol. Cell Biol. 13 (2012) 251–262.
[190] B. Schwer, M. Eckersdorff, Y. Li, J.C. Silva, D. Fermin, M.V. Kurtev, C. Giallourakis,
M.J. Comb, F.W. Alt, D.B. Lombard, Calorie restriction alters mitochondrial
protein acetylation, Aging Cell 8 (2009) 604–606.
[191] L.W. Finley, W. Haas, V. squiret-Dumas, D.C. Wallace, V. Procaccio, S.P. Gygi, M.C.
Haigis, Succinate dehydrogenase is a direct target of sirtuin 3 deacetylase activ-
ity, PLoS One 6 (2011) e23295.
[192] H. Cimen, M.J. Han, Y. Yang, Q. Tong, H. Koc, E.C. Koc, Regulation of succinate
dehydrogenase activity by SIRT3 in mammalian mitochondria, Biochemistry
49 (2010) 304–311.
[193] V.M. Gohil, S.A. Sheth, R. Nilsson, A.P. Wojtovich, J.H. Lee, F. Perocchi, W. Chen,
C.B. Clish, C. Ayata, P.S. Brookes, V.K. Mootha, Nutrient-sensitized screening for
drugs that shift energy metabolism frommitochondrial respiration to glycolysis,
Nat. Biotechnol. 28 (2010) 249–255.
[194] P. Dos Santos, A.J. Kowaltowski, M.N. Laclau, S. Seetharaman, P. Paucek, S.
Boudina, J.B. Thambo, L. Tariosse, K.D. Garlid, Mechanisms by which opening
the mitochondrial ATP-sensitive K(+) channel protects the ischemic heart,
Am. J. Physiol. Heart Circ. Physiol. 283 (2002) H284–H295.
[195] L.C. Alberici, H.C. Oliveira, P.R. Patricio, A.J. Kowaltowski, A.E. Vercesi, Hyperlipid-
emic mice present enhanced catabolism and higher mitochondrial ATP-sensitive
K + channel activity, Gastroenterology 131 (2006) 1228–1234.
[196] A.P. Halestrap, The regulation of the oxidation of fatty acids and other substrates
in rat heart mitochondria by changes in the matrix volume induced by osmotic
strength, valinomycin and Ca2+, Biochem. J. 244 (1987) 159–164.
[197] R. Guzun, N. Timohhina, K. Tepp, M. Gonzalez-Granillo, I. Shevchuk, V.
Chekulayev, A.V. Kuznetsov, T. Kaambre, V.A. Saks, Systems bioenergetics of cre-
atine kinase networks: physiological roles of creatine and phosphocreatine in
regulation of cardiac cell function, Amino Acids 40 (2011) 1333–1348.
[198] K.D. Garlid, S.P. Dos, Z.J. Xie, A.D. Costa, P. Paucek, Mitochondrial potassium
transport: the role of the mitochondrial ATP-sensitive K(+) channel in cardiac
function and cardioprotection, Biochim. Biophys. Acta 1606 (2003) 1–21.
[199] M.N. Laclau, S. Boudina, J.B. Thambo, L. Tariosse, G. Gouverneur, S.
Bonoron-Adele, V.A. Saks, K.D. Garlid, S.P. Dos, Cardioprotection by ischemic
preconditioning preserves mitochondrial function and functional coupling be-
tween adenine nucleotide translocase and creatine kinase, J. Mol. Cell. Cardiol.
33 (2001) 947–956.
[200] W. Rouslin, C.W. Broge, F. Guerrieri, G. Capozza, ATPase activity, IF1 content, and
proton conductivity of ESMP from control and ischemic slow and fast heart-rate
hearts, J. Bioenerg. Biomembr. 27 (1995) 459–466.[201] R. Cartoni, J.C. Martinou, Role of mitofusin 2 mutations in the physiopathology of
Charcot–Marie–Tooth disease type 2A, Exp. Neurol. 218 (2009) 268–273.
[202] S. Pich, D. Bach, P. Briones, M. Liesa, M. Camps, X. Testar, M. Palacin, A. Zorzano,
The Charcot–Marie–Tooth type 2A gene product, Mfn2, up-regulates fuel oxida-
tion through expression of OXPHOS system, Hum. Mol. Genet. 14 (2005)
1405–1415.
[203] J.M. Baughman, F. Perocchi, H.S. Girgis, M. Plovanich, C.A. Belcher-Timme, Y.
Sancak, X.R. Bao, L. Strittmatter, O. Goldberger, R.L. Bogorad, V. Koteliansky,
V.K. Mootha, Integrative genomics identiﬁes MCU as an essential component
of the mitochondrial calcium uniporter, Nature 476 (2011) 341–345.
[204] S.D. De, A. Raffaello, E. Teardo, I. Szabo, R. Rizzuto, A forty-kilodalton protein of
the inner membrane is the mitochondrial calcium uniporter, Nature 476
(2011) 336–340.
[205] J.N. Lorenz, N.R. Baird, L.M. Judd, W.T. Noonan, A. Andringa, T. Doetschman, P.A.
Manning, L.H. Liu, M.L. Miller, G.E. Shull, Impaired renal NaCl absorption in mice
lacking the ROMK potassium channel, a model for type II Bartter's syndrome,
J. Biol. Chem. 277 (2002) 37871–37880.
[206] L.M. Lewis, G. Bhave, B.A. Chauder, S. Banerjee, K.A. Lornsen, R. Redha, K. Fallen,
C.W. Lindsley, C.D. Weaver, J.S. Denton, High-throughput screening reveals a
small-molecule inhibitor of the renal outer medullary potassium channel and
Kir7.1, Mol. Pharmacol. 76 (2009) 1094–1103.
[207] J.P. Bayley JP, I. van Minderhout, P.C. Hogendoorn, C.J. Cornelisse, W.A. van der, F.A.
Prins, L. Teppema, A. Dahan, P. Devilee, P.E. Taschner, Sdhd and SDHD/H19 knockout
mice do not develop paraganglioma or pheochromocytoma, PLoS One 4 (2009) e7987.
[208] M.P. Puissegur, N.M. Mazure, T. Bertero, L. Pradelli, S. Grosso, K. Robbe-Sermesant,
T. Maurin, K. Lebrigand, B. Cardinaud, V. Hofman, S. Fourre, V. Magnone, J.E. Ricci,
J. Pouyssegur, P. Gounon, P. Hofman, P. Barbry, B. Mari, miR-210 is overexpressed
in late stages of lung cancer and mediates mitochondrial alterations associated
with modulation of HIF-1 activity, Cell Death Differ. 18 (2011) 465–478.
[209] A. Levitas, E. Muhammad, G. Harel, A. Saada, V.C. Caspi, E. Manor, J.C. Beck, V.
Shefﬁeld, R. Parvari, Familial neonatal isolated cardiomyopathy caused by a
mutation in the ﬂavoprotein subunit of succinate dehydrogenase, Eur. J. Hum.
Genet. 18 (2010) 1160–1165.
[210] A.T. Pagnamenta, I.P. Hargreaves, A.J. Duncan, J.W. Taanman, S.J. Heales, J.M.
Land, M. Bitner-Glindzicz, J.V. Leonard, S. Rahman, Phenotypic variability of mi-
tochondrial disease caused by a nuclear mutation in complex II, Mol. Genet.
Metab. 89 (2006) 214–221.
[211] B. Parfait, D. Chretien, A. Rotig, C. Marsac, A. Munnich, P. Rustin, Compound het-
erozygous mutations in the ﬂavoprotein gene of the respiratory chain complex II
in a patient with Leigh syndrome, Hum. Genet. 106 (2000) 236–243.
[212] C.R. Van, S. Seneca, J. Smet, H.R. Van, E. Gerlo, B. Devreese, B.J. Van, J.G. Leroy,
M.L. De, W. Lissens, Homozygous Gly555Glu mutation in the nuclear-encoded
70 kDa ﬂavoprotein gene causes instability of the respiratory chain complex II,
Am. J. Med. Genet. A 120A (2003) 13–18.
[213] N. Burnichon, J.J. Briere, R. Libe, L. Vescovo, J. Riviere, F. Tissier, E. Jouanno, X.
Jeunemaitre, P. Benit, A. Tzagoloff, P. Rustin, J. Bertherat, J. Favier, A.P.
Gimenez-Roqueplo, SDHA is a tumor suppressor gene causing paraganglioma,
Hum. Mol. Genet. 19 (2010) 3011–3020.
[214] S. Leckschat, D. Ream-Robinson, I.E. Schefﬂer, The gene for the iron sulfur pro-
tein of succinate dehydrogenase (SDH-IP) maps to human chromosome
1p35-36.1, Somat, Cell Mol. Genet. 19 (1993) 505–511.
[215] Y. Ni, K.M. Zbuk, T. Sadler, A. Patocs, G. Lobo, E. Edelman, P. Platzer, M.S. Orloff,
K.A. Waite, C. Eng, Germline mutations and variants in the succinate dehydroge-
nase genes in Cowden and Cowden-like syndromes, Am. J. Hum. Genet. 83
(2008) 261–268.
[216] K.A. Janeway, S.Y. Kim, M. Lodish, V. Nose, P. Rustin, J. Gaal, P.L. Dahia, B. Liegl,
E.R. Ball, M. Raygada, A.H. Lai, L. Kelly, J.L. Hornick, M. O'Sullivan, R.R. de
Krijger, W.N. Dinjens, G.D. Demetri, C.R. Antonescu, J.A. Fletcher, L. Helman,
C.A. Stratakis, Defects in succinate dehydrogenase in gastrointestinal stromal
tumors lacking KIT and PDGFRA mutations, Proc. Natl. Acad. Sci. U. S. A. 108
(2011) 314–318.
[217] S.R. McWhinney, B. Pasini, C.A. Stratakis, Familial gastrointestinal stromal
tumors and germ-line mutations, N. Engl. J. Med. 357 (2007) 1054–1056.
[218] B. Pasini, S.R. McWhinney, T. Bei, L. Matyakhina, S. Stergiopoulos, M. Muchow,
S.A. Boikos, B. Ferrando, K. Pacak, G. Assie, E. Baudin, A. Chompret, J.W. Ellison,
J.J. Briere, P. Rustin, A.P. Gimenez-Roqueplo, C. Eng, J.A. Carney, C.A. Stratakis,
Clinical and molecular genetics of patients with the Carney–Stratakis syndrome
and germline mutations of the genes coding for the succinate dehydrogenase
subunits SDHB, SDHC, and SDHD, Eur. J. Hum. Genet. 16 (2008) 79–88.
[219] F.M. Brouwers, G. Eisenhofer, J.J. Tao, J.A. Kant, K.T. Adams, W.M. Linehan, K.
Pacak, High frequency of SDHB germline mutations in patients with malignant
catecholamine-producing paragangliomas: implications for genetic testing,
J. Clin. Endocrinol. Metab. 91 (2006) 4505–4509.
[220] A. Cascon, C. Montero-Conde, S. Ruiz-Llorente, F. Mercadillo, R. Leton, C.
Rodriguez-Antona, B. Martinez-Delgado, M. Delgado, A. Diez, A. Rovira, J.A.
Diaz, M. Robledo, Gross SDHB deletions in patients with paraganglioma detected
by multiplex PCR: a possible hot spot? Genes Chromosomes Cancer 45 (2006)
213–219.
[221] J. Lima, T. Feijao, S.A. Ferreira da, I. Pereira-Castro, G. Fernandez-Ballester, V.
Maximo, A. Herrero, L. Serrano, M. Sobrinho-Simoes, G. Garcia-Rostan, High fre-
quency of germline succinate dehydrogenase mutations in sporadic cervical
paragangliomas in northern Spain: mitochondrial succinate dehydrogenase
structure–function relationships and clinical–pathological correlations, J. Clin.
Endocrinol. Metab. 92 (2007) 4853–4864.
[222] S. Vanharanta, M. Buchta, S.R. McWhinney, S.K. Virta, M. Peczkowska, C.D.
Morrison, R. Lehtonen, A. Januszewicz, H. Jarvinen, M. Juhola, J.P. Mecklin, E.
611A.P. Wojtovich et al. / Biochimica et Biophysica Acta 1827 (2013) 598–611Pukkala, R. Herva, M. Kiuru, N.N. Nupponen, L.A. Aaltonen, H.P. Neumann, C. Eng,
Early-onset renal cell carcinoma as a novel extraparaganglial component of
SDHB-associated heritable paraganglioma, Am. J. Hum. Genet. 74 (2004) 153–159.
[223] A.L. Young, B.E. Baysal, A. Deb, W.F. Young Jr., Familial malignant
catecholamine-secreting paraganglioma with prolonged survival associated
with mutation in the succinate dehydrogenase B gene, J. Clin. Endocrinol.
Metab. 87 (2002) 4101–4105.
[224] H.P. Neumann, B. Bausch, S.R. McWhinney, B.U. Bender, O. Gimm, G. Franke, J.
Schipper, J. Klisch, C. Altehoefer, K. Zerres, A. Januszewicz, C. Eng, W.M. Smith, R.
Munk, T. Manz, S. Glaesker, T.W. Apel, M. Treier, M. Reineke, M.K. Walz, C.
Hoang-Vu, M. Brauckhoff, A. Klein-Franke, P. Klose, H. Schmidt, M. Maier-Woelﬂe,
M. Peczkowska, C. Szmigielski, C. Eng, Germ-line mutations in nonsyndromic
pheochromocytoma, N. Engl. J. Med. 346 (2002) 1459–1466.
[225] B.E. Baysal, J.E. Willett-Brozick, P.A. Filho, E.C. Lawrence, E.N. Myers, R.E. Ferrell, An
Alu-mediated partial SDHC deletion causes familial and sporadic paraganglioma, J.
Med. Genet. 41 (2004) 703–709.
[226] H. Hirawake, M. Taniwaki, A. Tamura, S. Kojima, K. Kita, Cytochrome b in human
complex II (succinate–ubiquinone oxidoreductase): cDNA cloning of the com-
ponents in liver mitochondria and chromosome assignment of the genes for
the large (SDHC) and small (SDHD) subunits to 1q21 and 11q23, Cytogenet.
Cell Genet. 79 (1997) 132–138.
[227] S. Kytola, B. Nord, E.E. Elder, T. Carling, M. Kjellman, B. Cedermark, C. Juhlin, A.
Hoog, J. Isola, C. Larsson, Alterations of the SDHD gene locus in midgut carci-
noids, Merkel cell carcinomas, pheochromocytomas, and abdominal
paragangliomas, Genes Chromosomes Cancer 34 (2002) 325–332.
[228] R.F. Badenhop, S. Cherian, R.S. Lord, B.E. Baysal, P.E. Taschner, P.R. Schoﬁeld, Novel
mutations in the SDHD gene in pedigrees with familial carotid body paraganglioma
and sensorineural hearing loss, Genes Chromosomes Cancer 31 (2001) 255–263.
[229] A. Cascon, S. Ruiz-Llorente, A. Cebrian, D. Telleria, J.C. Rivero, J.J. Diez, P.J.
Lopez-Ibarra, M.A. Jaunsolo, J. Benitez, M. Robledo, Identiﬁcation of novel
SDHD mutations in patients with phaeochromocytoma and/or paraganglioma,
Eur. J. Hum. Genet. 10 (2002) 457–461.
[230] E.S. Jordanova, I. van Minderhout, P.C. Hogendoorn, P.E. Taschner, A.G. van Der Mey,
P. Devilee, C.J. Cornelisse, Somatic loss of maternal chromosome 11 causesparent-of-origin-dependent inheritance in SDHD-linked paraganglioma and
phaeochromocytoma families, Oncogene 23 (2004) 4076–4083.
[231] S.R. McWhinney, R.T. Pilarski, S.R. Forrester, M.C. Schneider, M.M. Sarquis, E.P.
Dias, C. Eng, Large germline deletions of mitochondrial complex II subunits
SDHB and SDHD in hereditary paraganglioma, J. Clin. Endocrinol. Metab. 89
(2004) 5694–5699.
[232] P.E. Taschner, J.C. Jansen, B.E. Baysal, A. Bosch, E.H. Rosenberg, A.H.
Brocker-Vriends, A.G. van Der Mey, G.J. van Ommen, C.J. Cornelisse, P. Devilee,
Nearly all hereditary paragangliomas in the Netherlands are caused by two
founder mutations in the SDHD gene, Genes Chromosomes Cancer 31 (2001)
274–281.
[233] O. Gimm, M. Armanios, H. Dziema, H.P. Neumann, C. Eng, Somatic and occult
germ-line mutations in SDHD, a mitochondrial complex II gene, in nonfamilial
pheochromocytoma, Cancer Res. 60 (2000) 6822–6825.
[234] D. Ghezzi, P. Goffrini, G. Uziel, R. Horvath, T. Klopstock, H. Lochmuller, P.
D'Adamo, P. Gasparini, T.M. Strom, H. Prokisch, F. Invernizzi, I. Ferrero, M.
Zeviani, SDHAF1, encoding a LYR complex-II speciﬁc assembly factor, is mutated
in SDH-defective infantile leukoencephalopathy, Nat. Genet. 41 (2009)
654–656.
[235] E.F. Hensen, D.N. van, J.C. Jansen, E.P. Corssmit, C.M. Tops, J.A. Romijn, A.H. Vriends,
A.G. van Der Mey, C.J. Cornelisse, P. Devilee, J.P. Bayley, High prevalence of founder
mutations of the succinate dehydrogenase genes in the Netherlands, Clin. Genet.
81 (2012) 284–288.
[236] T.A. Alston, L. Mela, H.J. Bright, 3-Nitropropionate, the toxic substance of
Indigofera, is a suicide inactivator of succinate dehydrogenase, Proc. Natl.
Acad. Sci. U. S. A. 74 (1977) 3767–3771.
[237] C.J. Coles, D.E. Edmondson, T.P. Singer, Inactivation of succinate dehydrogenase
by 3-nitropropionate, J. Biol. Chem. 254 (1979) 5161–5167.
[238] D.V. Dervartanian, C. Veeger, Studies on succinate dehydrogenase. I. Spectral
properties of the puriﬁed enzyme and formation of enzyme-competitive
inhibitor complexes, Biochim. Biophys. Acta 92 (1964) 233–247.
[239] E.B. Kearney, B.A. Ackrell, M. Mayr, Tightly bound oxalacetate and the activation
of succinate dehydrogenase, Biochem. Biophys. Res. Commun. 49 (1972)
1115–1121.
